

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 July 2004 (22.07.2004)

PCT

(10) International Publication Number
WO 2004/061105 A1

(51) International Patent Classification⁷: **C12N 15/12**,
15/861, 5/16, C07K 14/71, C12P 21/02, A61K 38/17,
48/00

(21) International Application Number:
PCT/EP2003/014997

(22) International Filing Date:
29 December 2003 (29.12.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/437,846 3 January 2003 (03.01.2003) US

(71) Applicant (for all designated States except US): **ISTI-
TUTO DI RICERCHE DI BIOLOGIA MOLECO-
LARE P. ANGELETTI SPA** [IT/IT]; Via Pontina Km.
30, 600, I-00040 Pomezia (Rome) (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CILIBERTO, Gen-
naro** [IT/IT]; IRBM, Via Pontina Km. 30, 600, I-00040
Pomezia (Rome) (IT). **LAHM, Armin** [DE/IT]; IRBM,

Via Pontina Km. 30, 600, I-00040 Pomezia (Rome) (IT).
LA MONICA, Nicola [IT/IT]; IRBM, Via Pontina Km.
30, 600, I-00040 Pomezia (Rome) (IT). **MONACI, Paolo**
[IT/IT]; IRBM, Via Pontina Km. 30, 600, I-00040 Pomezia
(Rome) (IT). **NUZZO, Maurizio** [IT/IT]; IRBM, Via Pon-
tina Km. 30, 600, I-00040 Pomezia (Rome) (IT).

(74) Agent: **MAN, Jocelyn**; Merck & Co., Inc., European
Patent Department, Terlings Park, Eastwick Road, Harlow,
Essex CM20 2QR (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

[Continued on next page]

(54) Title: **RHESUS HER2/NEU, NUCLEOTIDES ENCODING SAME, AND USES THEREOF**

Predicted Amino Acid Sequence of First Rhesus
Her2/Neu Protein (SEQ ID NO:2)

```
1 MELAAWYRWG LLLALLPPGA AGTQVCTGTD MKLRLPASPE THLDMLRHLY QGCQVVOGNI
61 ELTYLPTNAS LSLFQDIQEV QGYVLIAHNQ VRQVPLQRLR IVRGTQLFED NYALAVLDNG
121 DLLNNTTPVT GASPGLREL QLRSLTEILK GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA
181 LTLIDTNRSR ACHPCSPVCK GSRGWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC
241 AAGCTGPKHS DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
301 YNYLSTDVGS CTLYCPLHNQ EVTAEDGTOR CEKCSKPCAR VCYGLGMEHL REVRVTSAN
361 IQEFAGCKKI FGSFLAPLES FDGDPASNTA PLQPEQLRVF ETLEEITGYL YISAWPDSL
421 DLSVLQNLQV IRGRILHNGA YSLTLQGLGI SWLGLRSLRE LGSGLALIH NTRLCFVHTV
481 PWDQLFRNPQ QALLHTANRP EDECVGEGLA CHQLCARGHC WGPPTQCVN CSQFLRGQEC
541 VEECRVLQGL PREYVNAHRC LPCHPECQPP NGSVTCFGPE ADQCVACAHY KDPFFCVARC
601 PSGVKPDLIS MPIWKFPDEE GTCQSCPINC THSCVDLDDK GCPAEQRASP LTSIISAVVG
661 ILLVVVLGVV FGILIKRRQQ KIRKYTMRR LQETELVEPL TPSGAMPNQA QMRILKETEL
721 RKVKVLGSGA FGTVYKGIWI PDGENVKIPV AIKVLRENTS PKANKEILDE AYVMAGVGS
781 YVSRLLGICL TSTVQLVTQL MPYGCLLDHV RENRGLGSGQ DLLNWCQIA KGMSYLEDVR
841 LVHRDLAARN VLKSPNHVK ITDFGLARLL DIDETEYHAD GGVKPIKWA LESILRRRFT
901 HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID VYMIMVKCWM
961 IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGASPL DSTFYRSLLE DDDMGDLVDA
1021 EYLVPOQGF FCPDPAPGTG GMVHHRHS STRSGGDLT LGLEPSEEA PRSPAPSEG
1081 TGSDFVDFGL GMGAAGLQS LPAHDPSPQL RYSEDPTVPL PSETDGYVAP LTCSPQPEYV
1141 NQPDVRPQPP SPQEGPLSPA RPTGATLERP KTLSPGKNGV VKDVFAGGA VENPEYLAPR
1201 GGAAPQPHLP PAFSPAFDNL YYWQDPSEER GAPPSTFKGT PTAENPEYLG LDVPV*
```

(57) Abstract: Polynucleotides encoding rhesus monkey HER2/neu have been isolated, cloned and sequenced. The gene encoding the HER2/neu is commonly associated with the development of epithelial-derived human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the HER2/neu tumor-associated antigen, wherein aberrant HER2/neu expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector constructs carrying rhHER2/neu and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.

WO 2004/061105 A1



ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments*

Published:

— *with international search report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

TITLE OF THE INVENTION

RHESUS HER2/NEU, NUCLEOTIDES ENCODING SAME, AND USES THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority to U.S. Serial No. 60/437,846, filed January 3, 2003, which is hereby incorporated by reference.

FIELD OF THE INVENTION

The present invention relates generally to the detection and therapy of cancer. More specifically, the present invention relates to the rhesus monkey homologue of the tumor associated polypeptide HER2/neu, to isolated nucleic acid molecules which encode this protein, and to recombinant vectors and hosts comprising DNA encoding this protein. This invention also relates to adenoviral vector constructs carrying rhesus HER2/neu and to their use in vaccines and pharmaceutical compositions for preventing and treating cancer.

BACKGROUND OF THE INVENTION

Cancer typically involves the deregulation of genes that contribute to maintaining the cell cycle or controlling cell proliferation, such as growth factors and their receptors, oncogenes and tumor suppressor genes. The products of many of these genes are expressed on the surface of a wide variety of tumor cells and, hence, were designated tumor-associated antigens (TAA). Recent evidence supports the existence of tumor-associated antigens that are capable of eliciting an immune response, making these molecules a target for vaccine therapy. Because many of these gene products are also expressed in normal cells, albeit at lower levels, many cancer vaccines targeting tumor-associated antigens have proven ineffective due to immunotolerance.

The product of the HER2/neu proto-oncogene (also called c-erbB-2) is a transmembrane TAA that is a member of the epidermal growth factor receptor family. The HER2/neu gene was originally cloned from a rat neuroglioblastoma (Shih et al., *Nature* 290: 261-264 (1981)) and later isolated and characterized from human cells (Coussens et al., *Science* 230: 1132-39 (1985); King et al., *Science* 229: 974-76 (1985)). To date, no simian homologs of HER2/neu are available.

HER2/neu has been further classified as a member of the HER family of receptor tyrosine kinases, which consists of four receptors that participate in cell growth and differentiation. The HER receptors contribute to maintaining normal cell growth by binding growth factor ligands as dimers, thereby initiating intracellular signaling cascades which

ultimately result in the activation of genes important in cell growth. Although several ligands have been identified for other members of the HER family, a high affinity ligand for the HER2/neu receptor has yet to be found (Lohrisch and Piccart, *Semin. Oncol.* 28(6): Suppl. 18: 3-11 (2001)).

Low levels of expression of the HER2/neu transcript and the encoded 185 kD protein were detected in normal adult epithelial cells of various tissues, including the skin and breast, and tissues of the gastrointestinal, reproductive and urinary tracts (Press et al., *Oncogene* 5: 953-962 (1990)). Higher levels of HER2/neu expression were also detected in the corresponding fetal tissues during embryonic development (Press et al., *supra*).

HER2/neu is commonly overexpressed or amplified in various malignancies such as carcinomas of the breast, ovary, uterus, colon, and prostate, and adenocarcinomas of the lung (reviewed in Disis and Cheever, *Adv. Cancer Research* 71: 343-371 (1997)). Such overexpression of HER2/neu correlates with a poor prognosis and a higher relapse rate for cancer patients (Slamon et al., *Science* 244: 707-712 (1989)).

Many cancer patients suffering from malignancies associated with HER2/neu overexpression have had immune responses against the protein product of the HER2/neu oncogene, thus making HER2/neu an immunological target for the development of cancer therapeutics. An effective vaccine exploiting this immune response to HER2/neu must both enhance this immunity to a level that is protective and/or preventive and overcome self-tolerance.

HER2/neu has been proposed as a target for the development of immunological treatments of different malignancies. Different anti-HER2 monoclonal antibodies have been investigated as therapies for breast cancer, with each antibody demonstrating various levels of success (for discussion, see Yarden, *Oncology* 61(suppl 2): 1-13 (2001)). Amici et al. (U.S. Patent No. 6,127,344) disclose a method for inducing immunity against HER2/neu by administering an expression vector comprising the full-length human HER2/neu cDNA functionally linked to the human cytomegalovirus promoter. Cheever and Disis disclose methods for immunizing humans against HER2/neu-associated cancers with HER2 peptides (U.S. Patent No. 5,846,538). Additionally, HER2/neu peptide-based vaccines have been studied in rodent models (for review, see Disis and Cheever, *Advances in Cancer Research* 71:343-71 (1997)).

Despite the identification of the HER2/neu clones mentioned above, it would be highly desirable to identify additional mammalian genes encoding HER2/neu to allow for the development of a cancer vaccine which is efficacious and not hindered by self-tolerance.

SUMMARY OF THE INVENTION

The present invention relates to isolated or purified nucleic acid molecules (polynucleotides) comprising a sequence of nucleotides that encode a novel rhesus monkey HER2/neu protein (also called c-erbB-2, hereinafter designated rhHER2/neu) as set forth in SEQ ID NO:2 and SEQ ID NO:41. The DNA molecules disclosed herein may be transfected into a host cell of choice wherein the recombinant host cell provides a source for substantial levels of an expressed functional rhHER2/neu protein (SEQ ID NO:2 or SEQ ID NO:41).

The present invention further relates to an isolated nucleic acid molecule which encodes mRNA that expresses a novel rhesus monkey HER2/neu protein; this DNA molecule comprising the nucleotide sequence disclosed herein as SEQ ID NO:1. A preferred aspect of this portion of the present invention is disclosed in FIGURE 1, which shows a DNA molecule (SEQ ID NO:1) that encodes a novel rhHER2/neu protein (SEQ ID NO:2).

The present invention also provides an isolated nucleic acid molecule which encodes mRNA that expresses a novel rhesus monkey HER2/neu protein; this DNA molecule comprising the nucleotide sequence disclosed herein as SEQ ID NO:40. A preferred aspect of this portion of the present invention is disclosed in FIGURE 5, which shows a DNA molecule (SEQ ID NO:40) that encodes a novel rhHER2/neu protein (SEQ ID NO:41).

The present invention also relates to recombinant vectors and recombinant host cells, both prokaryotic and eukaryotic, which contain the nucleic acid molecules disclosed throughout this specification.

The present invention further relates to a process for expressing a rhesus monkey HER2/neu protein in a recombinant host cell, comprising: (a) introducing a vector comprising the nucleic acid as set forth in SEQ ID NO:1 or SEQ ID NO:40 into a suitable host cell; and, (b) culturing the host cell under conditions which allow expression of said rhesus monkey HER2/neu protein.

A preferred aspect of the present invention is a substantially purified form of a rhesus monkey HER2/neu protein which consists of the amino acid sequence disclosed in FIGURE 2 (SEQ ID NO:2).

A preferred aspect of the present invention is a substantially purified form of a rhesus monkey HER2/neu protein which consists of the amino acid sequence disclosed in FIGURE 6 (SEQ ID NO:41).

Yet another preferred aspect of the present invention relates to a substantially purified, fully processed (including proteolytic processing, glycosylation and/or phosphorylation), mature rhHER2/neu protein obtained from a recombinant host cell containing a DNA expression vector comprising nucleotide sequence as set forth in SEQ ID NO:1 or SEQ

ID NO:40, which express the rhHER2/neu protein. It is especially preferred that the recombinant host cell be a eukaryotic host cell, such as a mammalian cell line.

Another aspect of this invention is a method of preventing or treating cancer comprising administering to a mammal a vaccine vector comprising an isolated nucleic acid molecule, the isolated nucleic acid molecule comprising a sequence of nucleotides that encodes a rhesus monkey HER2/neu protein as set forth in SEQ ID NO:2 or SEQ ID NO:41.

The present invention further relates to an adenovirus vaccine vector comprising an adenoviral genome with a deletion in the E1 and E3 regions, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising: (a) a polynucleotide encoding a rhesus monkey HER2/neu protein; and (b) a promoter operably linked to the polynucleotide.

The present invention also relates to a vaccine plasmid comprising a plasmid portion and an expression cassette portion, the expression cassette portion comprising: (a) a polynucleotide encoding a rhesus monkey HER2/neu protein; and (b) a promoter operably linked to the polynucleotide.

Another aspect of the present invention is a method of protecting or a mammal from cancer or treating a mammal suffering from cancer comprising: (a) introducing into the mammal a first vector comprising: i) a polynucleotide encoding a rhesus monkey HER2/neu protein; and ii) a promoter operably linked to the polynucleotide; (b) allowing a predetermined amount of time to pass; and (c) introducing into the mammal a second vector comprising: i) a polynucleotide encoding a rhesus monkey HER2/neu protein; and ii) a promoter operably linked to the polynucleotide.

As used throughout the specification and in the appended claims, the singular forms "a," "an," and "the" include the plural reference unless the context clearly dictates otherwise.

As used throughout the specification and appended claims, the following definitions and abbreviations apply:

The term "promoter" refers to a recognition site on a DNA strand to which the RNA polymerase binds. The promoter forms an initiation complex with RNA polymerase to initiate and drive transcriptional activity. The complex can be modified by activating sequences termed "enhancers" or inhibiting sequences termed "silencers".

The term "cassette" refers to the sequence of the present invention that contains the nucleic acid sequence which is to be expressed. The cassette is similar in concept to a cassette tape; each cassette has its own sequence. Thus by interchanging the cassette, the vector will express a different sequence. Because of the restriction sites at the 5' and 3' ends, the cassette can be easily inserted, removed or replaced with another cassette.

The term "vector" refers to some means by which DNA fragments can be introduced into a host organism or host tissue. There are various types of vectors including plasmid, virus (including adenovirus), bacteriophages and cosmids.

The term "first generation," as used in reference to adenoviral vectors, describes said adenoviral vectors that are replication-defective. First generation adenovirus vectors typically have a deleted or inactivated E1 gene region, and preferably have a deleted or inactivated E3 gene region.

The designation "pMRKAd5-rhHER2/neu" refers to a plasmid construct, disclosed herein, which comprises an Ad5 adenoviral genome deleted of the E1 and E3 regions. In this plasmid, the E1 region is replaced by a rhesus HER2/neu gene in an E1 parallel orientation, under the control of a human CMV promoter without intron A, followed by a bovine growth hormone polyadenylation signal.

The designation "MRKAd5-rhHER2/neu" refers to the virus generated from plasmid pMRKAD5-rhHER2/neu following removal of plasmid sequences by restriction and transfection into an E1-expressing cell line, such as Per.C6 or HEK 293.

The designation "pV1J-rhHER2/neu" refers to a plasmid construct disclosed herein comprising the human CMV immediate-early (IE) promoter and intron A, a full-length rhesus HER2/neu gene, a bovine growth hormone-derived polyadenylation and transcriptional termination sequences, and a minimal pUC backbone.

The term "first rhesus HER2/neu DNA sequence," as used interchangeably with the term "rhHER2#1," refers to the rhesus HER2/neu sequence as identified and isolated herein in EXAMPLE 1 and set forth in SEQ ID NO:1. This sequence was translated to determine the amino acid sequence of the "first rhesus HER2/neu protein," as set forth in SEQ ID NO:2.

The term "second rhesus HER2/neu DNA sequence," as used interchangeably with the term "rhHER2#2," refers to the rhesus HER2/neu sequence as identified and isolated herein in EXAMPLE 4 and set forth in SEQ ID NO:40. This DNA molecule was isolated from a different rhesus monkey than the DNA molecule described in EXAMPLE 1. This sequence was translated to deduce the amino acid sequence of the "second rhesus HER2/neu protein," as set forth in SEQ ID NO:41. Differences between the rhHER2#1 and rhHER2#2 nucleotide and amino acid sequences are detailed in FIGURE 7.

The term "effective amount" means sufficient vaccine composition is introduced to produce the adequate levels of the polypeptide, so that an immune response results. One skilled in the art recognizes that this level may vary.

"Substantially free from other nucleic acids" means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%, free of other nucleic acids. As used

interchangeably, the terms “substantially free from other nucleic acids,” “substantially purified,” “isolated nucleic acid” or “purified nucleic acid” also refer to DNA molecules which comprise a coding region for a rhesus HER2/neu protein that has been purified away from other cellular components. Thus, a rhesus HER2/neu DNA preparation that is substantially free from other nucleic acids will contain, as a percent of its total nucleic acid, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-rhesus HER2/neu nucleic acids. Whether a given rhesus HER2/neu DNA preparation is substantially free from other nucleic acids can be determined by such conventional techniques of assessing nucleic acid purity as, *e.g.*, agarose gel electrophoresis combined with appropriate staining methods, *e.g.*, ethidium bromide staining, or by sequencing.

“Substantially free from other proteins” or “substantially purified” means at least 90%, preferably 95%, more preferably 99%, and even more preferably 99.9%, free of other proteins. Thus, a rhesus monkey HER2/neu protein preparation that is substantially free from other proteins will contain, as a percent of its total protein, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-rhesus monkey HER2/neu proteins. Whether a given rhesus monkey HER2/neu protein preparation is substantially free from other proteins can be determined by such conventional techniques of assessing protein purity as, *e.g.*, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) combined with appropriate detection methods, *e.g.*, silver staining or immunoblotting.

As used interchangeably, the terms “substantially free from other proteins” or “substantially purified,” or “isolated rhesus monkey HER2/neu protein” or “purified rhesus monkey HER2/neu protein” also refer to rhesus monkey HER2/neu protein that has been isolated from a natural source. Use of the term “isolated” or “purified” indicates that rhesus monkey HER2/neu protein has been removed from its normal cellular environment. Thus, an isolated rhesus monkey HER2/neu protein may be in a cell-free solution or placed in a different cellular environment from that in which it occurs naturally. The term isolated does not imply that an isolated rhesus monkey HER2/neu protein is the only protein present, but instead means that an isolated rhHER2/neu protein is substantially free of other proteins and non-amino acid material (*e.g.*, nucleic acids, lipids, carbohydrates) naturally associated with the rhHER2/neu protein *in vivo*. Thus, a rhesus monkey HER2/neu protein that is recombinantly expressed in a prokaryotic or eukaryotic cell and substantially purified from this host cell which does not naturally (*i.e.*, without intervention) express this rhHER2/neu protein is of course “isolated rhesus monkey HER2/neu protein” under any circumstances referred to herein. As noted above, a rhHER2/neu protein preparation that is an isolated or purified rhHER2/neu protein will be

substantially free from other proteins and will contain, as a percent of its total protein, no more than 10%, preferably no more than 5%, more preferably no more than 1%, and even more preferably no more than 0.1%, of non-rhesus monkey HER2/neu proteins.

A "conservative amino acid substitution" refers to the replacement of one amino acid residue by another, chemically similar, amino acid residue. Examples of such conservative substitutions are: substitution of one hydrophobic residue (isoleucine, leucine, valine, or methionine) for another; substitution of one polar residue for another polar residue of the same charge (e.g., arginine for lysine; glutamic acid for aspartic acid).

The term "mammalian" refers to any mammal, including a human being.

The abbreviation "Ag" refers to an antigen.

The abbreviations "Ab" and "mAb" refer to an antibody and a monoclonal antibody, respectively.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1 shows the nucleotide sequence of the first rhesus monkey HER2/neu cDNA, as set forth in SEQ ID NO:1 (see EXAMPLE 1). The presence of an "R" at position 795 indicates that either an A or a G is located at that position.

FIGURE 2 shows the predicted amino acid sequence of rhesus monkey HER2/neu protein, as set forth in SEQ ID NO:2. The amino acid sequence shown was deduced from the nucleotide sequence disclosed as SEQ ID NO:1.

FIGURE 3 discloses the nucleotide sequences of oligonucleotide primers spanning the HER2/neu gene, which were used to generate a series of rhesus HER2/neu fragments by RT-PCR (see EXAMPLE 1). Columns marked "Forward" and "Reverse" state the location of the primers with respect to the published human HER2/neu sequence (Accession M11730). Primers disclosed as SEQ ID NOs: 15 and 16 were designed to mutate amino acid position 579 from K to A, to inactivate the tyrosine kinase activity of the translated protein. Primers 3388-3410 and 3410-3388 have a sequence with a C at position 15 and a G at position 10, respectively, which code for Ser (AGC). In contrast, the Rhesus HER2/neu sequence has a T at that position, coding again for Ser (AGT). These primers were used for sequencing, but not for cloning purposes. For SEQ ID NOs: 11 and 19, sequence priming on rhHER2/neu is underlined.

FIGURE 4 shows the sequences of RT-PCR primers used to construct the full-length rhesus HER2/neu clone (see EXAMPLE 2). The first column lists the reaction number corresponding to the reactions discussed in EXAMPLE 2. Each row depicts a set of forward and reverse primers used to generate the clones listed in column 4. Nomenclature for the clones

indicates both the vector used for cloning (BS or CR for pBluescript or pCRII, respectively) and the location of the sequence relative to the published human HER2/neu sequence (listed as numbers).

FIGURE 5 shows the nucleotide sequence of the second rhesus monkey HER2/neu cDNA, as set forth in SEQ ID NO:40 (see EXAMPLE 4). The presence of an "R" within the nucleotide sequence indicates that either an "A" or a "G" is located at that position. The presence of a "Y" within the sequence indicates that a "C" or a "T" is located at that position. Nucleotide bases that are different from the corresponding bases of the first rhesus HER2/neu (SEQ ID NO:1) are bold and underlined.

FIGURE 6 shows the predicted amino acid sequence of the second rhesus monkey HER2/neu protein, as set forth in SEQ ID NO:41 (see EXAMPLE 4). The amino acid sequence shown was deduced from the nucleotide sequence disclosed as SEQ ID NO:40. The "X" at position 517 indicates that a "Q" (Gln) or an "R" (Arg) may be present at that position. The "X" at position 647 indicates that a "K" (Lys) or an "R" (Arg) may be present at that position. The "X" at position 1075 indicates that an "R" (Arg) or a "Q" (Gln) may be present at that position.

FIGURE 7 details the specific mutations present in the second rhesus HER2/neu DNA and protein sequences (RhHER2#2, SEQ ID NOs:40 and 41) as compared to the first rhesus HER2/neu DNA and protein sequences (RhHER2#1, SEQ ID NOs: 1 and 2). The first column in each table lists the position of nucleotides that are different between RhHER2#2 and RhHER2#1. The second column in each table list the number of specific clones carrying HER2/neu fragments that were isolated and used to determine the sequence of RhHER2#1 and RhHER2#2, respectively. The third column in each table shows the sequence of the codon in which the differences occur, with dissimilar nucleotides highlighted. Below the codons are the one-letter amino acid symbols for the resulting amino acids, highlighted in gray.

DETAILED DESCRIPTION OF THE INVENTION

The gene encoding the HER2/neu tumor-associated antigen is commonly associated with the development of epithelial-derived human carcinomas. The present invention relates to compositions and methods to elicit or enhance immunity to the protein product expressed by the HER2/neu tumor-associated antigen, wherein aberrant HER2/neu expression is associated with the carcinoma or its development. Association of aberrant HER2/neu expression with a carcinoma does not require that the HER2/neu protein be expressed in tumor tissue at all timepoints of its development, as abnormal HER2/neu expression may be present at tumor initiation and not be detectable late into tumor progression.

To this end, polynucleotides encoding rhesus monkey HER2/neu are provided. The molecules of the present invention may be used in a recombinant adenovirus vaccine to provide effective immunoprophylaxis against epithelial-derived carcinomas through cell-mediated immunity. When directly introduced into a vertebrate *in vivo*, the invention polynucleotides induce the expression of encoded proteins within the animal, including mammals such as primates, dogs and humans.

The present invention relates to an isolated nucleic acid molecule (polynucleotide) comprising a sequence of nucleotides which encodes mRNA that expresses a novel rhHER2/neu protein as set forth in SEQ ID NO:2. The present invention also relates to an isolated nucleic acid molecule comprising a sequence of nucleotides which encodes mRNA that expresses a novel rhHER2/neu protein as set forth in SEQ ID NO:41. The nucleic acid molecules of the present invention are substantially free from other nucleic acids.

The isolated nucleic acid molecules of the present invention may include a deoxyribonucleic acid molecule (DNA), such as genomic DNA and complementary DNA (cDNA), which may be single (coding or noncoding strand) or double stranded, as well as synthetic DNA, such as a synthesized, single stranded polynucleotide. The isolated nucleic acid molecules of the present invention may also include a ribonucleic acid molecule (RNA). For most cloning purposes, DNA is a preferred nucleic acid.

A preferred DNA molecule of the present invention comprises the nucleotide sequence disclosed herein as SEQ ID NO:1, shown in FIGURE 1, which encodes the rhesus HER2/neu protein shown in FIGURE 2 and set forth as SEQ ID NO:2. This rhHER2/neu nucleic acid molecule was identified through RT-PCR as described in detail in EXAMPLE 1. The presence of an "R" at position 795 of SEQ ID NO:1 indicates that clones isolated from the first rhesus monkey comprised either an A or a G at that position. A nucleic acid molecule isolated from the first rhesus monkey and comprising an "A" at position 795 is designated herein SEQ ID NO:42. A nucleic acid molecule isolated from the first rhesus monkey and comprising a "G" at position 795 is designated herein SEQ ID NO:43.

A second preferred DNA molecule comprises the nucleotide sequence disclosed herein as SEQ ID NO:40, shown in FIGURE 5, which encodes the rhesus HER2/neu protein shown in FIGURE 6 and set forth as SEQ ID NO:41. The isolated cDNA clones, associated vectors, hosts, recombinant subcellular fractions and membranes, and the expressed and mature forms of rhHER2/neu are useful for the development of a cancer vaccine.

The present invention also includes biologically active fragments or mutants of SEQ ID NO:1 or SEQ ID NO:40, which encode mRNA expressing novel rhHER2/neu proteins. Any such biologically active fragment and/or mutant will encode either a protein or protein

fragment which at least substantially mimics the pharmacological properties of the rhHER2/neu protein, including but not limited to the rhHER2/neu proteins as set forth in SEQ ID NO:2 and SEQ ID NO:41. Any such polynucleotide includes but is not necessarily limited to: nucleotide substitutions, deletions, additions, amino-terminal truncations and carboxy-terminal truncations. The mutations of the present invention encode mRNA molecules that express a functional rhHER2/neu protein in a eukaryotic cell so as to be useful in cancer vaccine development.

This invention also relates to synthetic DNA that encodes the rhHER2/neu protein where the nucleotide sequence of the synthetic DNA differs significantly from the nucleotide sequence of SEQ ID NO:1 and SEQ ID NO:40, but still encodes the same rhHER2/neu protein as SEQ ID NO:2 or SEQ ID NO:41. Such synthetic DNAs are intended to be within the scope of the present invention.

Therefore, the present invention discloses codon redundancy that may result in numerous DNA molecules expressing an identical protein. For purposes of this specification, a sequence bearing one or more replaced codons will be defined as a degenerate variation. Also included within the scope of this invention are mutations either in the DNA sequence or the translated protein that do not substantially alter the ultimate physical properties of the expressed protein. For example, substitution of valine for leucine, arginine for lysine, or asparagine for glutamine may not cause a change in the functionality of the polypeptide.

It is known that DNA sequences coding for a peptide may be altered so as to code for a peptide that has properties that are different than those of the naturally occurring peptide. Methods of altering the DNA sequences include but are not limited to site directed mutagenesis. Examples of altered properties include but are not limited to changes in the affinity of an enzyme for a substrate or receptor for a ligand.

Included in the present invention are DNA sequences that hybridize to SEQ ID NO:1 or SEQ ID NO:40 under stringent conditions. By way of example, and not limitation, a procedure using conditions of high stringency is as follows: Prehybridization of filters containing DNA is carried out for 2 hours to overnight at 65°C in buffer composed of 6X SSC, 5X Denhardt's solution, and 100 µg/ml denatured salmon sperm DNA. Filters are hybridized for 12 to 48 hrs at 65°C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10⁶ cpm of ³²P-labeled probe. Washing of filters is done at 37°C for 1 hr in a solution containing 2X SSC, 0.1% SDS. This is followed by a wash in 0.1X SSC, 0.1% SDS at 50°C for 45 min. before autoradiography. Other procedures using conditions of high stringency would include either a hybridization step carried out in 5XSSC, 5X Denhardt's solution, 50% formamide at 42°C for 12 to 48 hours or a washing step carried out in 0.2X SSPE, 0.2% SDS at 65°C for 30 to 60 minutes.

Reagents mentioned in the foregoing procedures for carrying out high stringency hybridization are well known in the art. Details of the composition of these reagents can be found in, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989 which is hereby incorporated by reference. In addition to the foregoing, other conditions of high stringency which may be used are well known in the art.

A preferred aspect of the present invention is a substantially purified form of a rhesus monkey HER2/neu protein which comprises a sequence of amino acids as disclosed in FIGURE 2 (SEQ ID NO:2).

Another preferred aspect of the present invention is a substantially purified form of a rhesus monkey HER2/neu protein which comprises a sequence of amino acids as disclosed in FIGURE 6 (SEQ ID NO:41).

This invention also relates to various functional domains of rhHER2/neu, such as the extracellular domain and the intracellular domain, and to hybrid molecules comprising at least one of these sequences.

The present invention also includes biologically active fragments and/or mutants of a rhHER2/neu protein, comprising the amino acid sequence as set forth in SEQ ID NO: 2 or SEQ ID NO:41, including but not necessarily limited to amino acid substitutions, deletions, additions, amino terminal truncations and carboxy-terminal truncations such that these mutations provide for proteins or protein fragments of diagnostic, therapeutic or prophylactic use and would be useful for cancer vaccine development.

The rhesus monkey HER2/neu proteins of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The present invention also relates to rhHER2/neu fusion constructs, including but not limited to fusion constructs which express a portion of the rhesus HER2/neu protein linked to various markers, including but in no way limited to GFP (Green fluorescent protein), the MYC epitope, GST, and Fc. Any such fusion construct may be expressed in the cell line of interest and used to screen for modulators of the rhesus HER2/neu protein disclosed herein.

The present invention further relates to recombinant vectors that comprise the substantially purified nucleic acid molecules disclosed throughout this specification. These vectors may be comprised of DNA or RNA. For most cloning purposes, DNA vectors are preferred. Typical vectors include plasmids, modified viruses, bacteriophage, cosmids, yeast

artificial chromosomes, and other forms of episomal or integrated DNA that can encode a rhHER2/neu protein. It is well within the purview of the skilled artisan to determine an appropriate vector for a particular gene transfer or other use.

An expression vector containing DNA encoding a rhHER2/neu protein may be used for expression of rhHER2/neu in a recombinant host cell. Expression vectors may include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed plasmids or viruses. Also, a variety of bacterial expression vectors may be used to express recombinant rhHER2/neu in bacterial cells if desired. In addition, a variety of fungal cell expression vectors may be used to express recombinant rhHER2/neu in fungal cells. Further, a variety of insect cell expression vectors may be used to express recombinant protein in insect cells.

The present invention also relates to host cells transformed or transfected with vectors comprising the nucleic acid molecules of the present invention. Recombinant host cells may be prokaryotic or eukaryotic, including but not limited to, bacteria such as *E. coli*, fungal cells such as yeast, mammalian cells including, but not limited to, cell lines of bovine, porcine, monkey and rodent origin; and insect cells including but not limited to *Drosophila* and silkworm derived cell lines. Such recombinant host cells can be cultured under suitable conditions to produce rhHER2/neu or a biologically equivalent form.

As noted above, an expression vector containing DNA encoding a rhHER2/neu protein may be used for expression of rhHER2/neu in a recombinant host cell. Therefore, another aspect of this invention is a process for expressing a rhesus monkey HER2/neu protein in a recombinant host cell, comprising: (a) introducing a vector comprising the nucleic acid of as set forth in SEQ ID NO:1 or SEQ ID NO:40 into a suitable host cell; and, (b) culturing the host cell under conditions which allow expression of said rhesus monkey HER2/neu protein.

Following expression of rhHER2/neu in a host cell, rhHER2/neu protein may be recovered to provide rhHER2/neu protein in active form. Several rhHER2/neu protein purification procedures are available and suitable for use. Recombinant rhHER2/neu protein may be purified from cell lysates and extracts by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography. In addition, recombinant rhHER2/neu protein can be separated from other cellular proteins by use of an immunoaffinity column made with monoclonal or polyclonal antibodies specific for full-length rhHER2/neu protein, or polypeptide fragments of rhHER2/neu protein.

The nucleic acids of the present invention may be assembled into an expression cassette that comprises sequences designed to provide for efficient expression of the protein in a human cell. The cassette preferably contains the full-length rhHER2/neu gene, with related

transcriptional and translations control sequences operatively linked to it, such as a promoter, and termination sequences. In a preferred embodiment, the promoter is the cytomegalovirus promoter without the intron A sequence, although those skilled in the art will recognize that any of a number of other known promoters such as the strong immunoglobulin, or other eukaryotic gene promoters may be used. A preferred transcriptional terminator is the bovine growth hormone terminator, although other known transcriptional terminators may also be used. The combination of CMV-BGH terminator is particularly preferred.

In accordance with this invention, the rhesus HER2/neu expression cassette is inserted into a vector. The vector is preferably an adenoviral vector, although linear DNA linked to a promoter, or other vectors, such as adeno-associated virus or a modified vaccinia virus vector may also be used.

If the vector chosen is an adenovirus, it is preferred that the vector be a so-called first-generation adenoviral vector. These adenoviral vectors are characterized by having a non-functional E1 gene region, and preferably a deleted adenoviral E1 gene region. In some embodiments, the expression cassette is inserted in the position where the adenoviral E1 gene is normally located. In addition, these vectors optionally have a non-functional or deleted E3 region. It is preferred that the adenovirus genome used be deleted of both the E1 and E3 regions ($\Delta E1\Delta E3$). The adenoviruses can be multiplied in known cell lines which express the viral E1 gene, such as 293 cells, or PERC.6 cells, or in cell lines derived from 293 or PERC.6 cell which are transiently or stably transformed to express an extra protein. For examples, when using constructs that have a controlled gene expression, such as a tetracycline regulatable promoter system, the cell line may express components involved in the regulatory system. One example of such a cell line is T-Rex-293; others are known in the art.

For convenience in manipulating the adenoviral vector, the adenovirus may be in a shuttle plasmid form. This invention is also directed to a shuttle plasmid vector which comprises a plasmid portion and an adenovirus portion, the adenovirus portion comprising an adenoviral genome which has a deleted E1 and optional E3 deletion, and has an inserted expression cassette comprising rhesus HER2/neu. In preferred embodiments, there is a restriction site flanking the adenoviral portion of the plasmid so that the adenoviral vector can easily be removed. The shuttle plasmid may be replicated in prokaryotic cells or eukaryotic cells.

In a preferred embodiment of the invention, the expression cassette is inserted into the pMRKAd5-HV0 adenovirus plasmid (*See Emini et al., WO 02/22080, which is hereby incorporated by reference*). This plasmid comprises an Ad5 adenoviral genome deleted of the E1 and E3 regions. The design of the pMRKAd5-HV0 plasmid was improved over prior

adenovectors by extending the 5' cis-acting packaging region further into the E1 gene to incorporate elements found to be important in optimizing viral packaging, resulting in enhanced virus amplification. Advantageously, this enhanced adenoviral vector is capable of maintaining genetic stability following high passage propagation.

Standard techniques of molecular biology for preparing and purifying DNA constructs enable the preparation of the adenoviruses, shuttle plasmids, and DNA immunogens of this invention.

The vectors described above may be used in immunogenic compositions and vaccines for preventing the development of epithelial-derived carcinomas associated with aberrant HER2/neu expression and/or for treating existing cancers. To this end, one aspect of the instant invention is a method of preventing or treating cancer comprising administering to a mammal a vaccine vector comprising an isolated nucleic acid molecule, the isolated nucleic acid molecule comprising a sequence of nucleotides that encodes a rhesus monkey HER2/neu protein as set forth in SEQ ID NO:2 or SEQ ID NO:41.

In accordance with the method described above, the vaccine vector may be administered for the treatment or prevention of cancer in any mammal. In a preferred embodiment of the invention, the mammal is a human.

Further, one of skill in the art may choose any type of vector for use in the treatment and prevention method described. Preferably, the vector is an adenovirus vector or a plasmid vector. In a preferred embodiment of the invention, the vector is an adenoviral vector comprising an adenoviral genome with a deletion in the adenovirus E1 region, and an insert in the adenovirus E1 region, wherein the insert comprises an expression cassette comprising: (a) a polynucleotide encoding a rhesus monkey HER2/neu protein; and (b) a promoter operably linked to the polynucleotide.

The instant invention further relates to an adenovirus vaccine vector comprising an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising: (a) a polynucleotide encoding a rhesus monkey HER2/neu protein; and (b) a promoter operably linked to the polynucleotide.

In a preferred embodiment of this aspect of the invention, the adenovirus vector is an Ad 5 vector.

In another aspect, the invention relates to a vaccine plasmid comprising a plasmid portion and an expression cassette portion, the expression cassette portion comprising: (a) a polynucleotide encoding a rhesus monkey HER2/neu protein; and (b) a promoter operably linked to the polynucleotide.

In some embodiments of this invention, the recombinant adenovirus vaccines disclosed herein are used in various prime/boost combinations with a plasmid-based polynucleotide vaccine in order to induce an enhanced immune response. In this case, the two vectors are administered in a "prime and boost" regimen. For example the first type of vector is administered, then after a predetermined amount of time, for example, 1 month, 2 months, six months, or other appropriate interval, a second type of vector is administered. Preferably the vectors carry expression cassettes encoding the same polynucleotide or combination of polynucleotides. In the embodiment where a plasmid DNA is also used, it is preferred that the vector contain one or more promoters recognized by mammalian or insect cells. In a preferred embodiment, the plasmid would contain a strong promoter such as, but not limited to, the human CMV promoter. The rhesus HER2/neu gene or other gene to be expressed would be linked to such a promoter. An example of such a plasmid would be the mammalian expression plasmid V1Jns as described (J. Shiver et. al. in *DNA Vaccines*, M. Liu et al. eds., N.Y. Acad. Sci., N.Y., 772:198-208 (1996), which is herein incorporated by reference).

As stated above, an adenoviral vector vaccine and a plasmid vaccine may be administered to a vertebrate as part of a single therapeutic regime to induce an immune response. To this end, the present invention relates to a method of protecting a mammal from cancer comprising: (a) introducing into the mammal a first vector comprising: i) a polynucleotide encoding a rhesus monkey HER2/neu protein; and ii) a promoter operably linked to the polynucleotide; (b) allowing a predetermined amount of time to pass; and (c) introducing into the mammal a second vector comprising: i) a polynucleotide encoding a rhesus monkey HER2/neu protein; and ii) a promoter operably linked to the polynucleotide.

In one embodiment of the method of protection described above, the first vector is a plasmid and the second vector is an adenovirus vector. In an alternative embodiment, the first vector is an adenovirus vector and the second vector is a plasmid.

The instant invention further relates to a method of treating a mammal suffering from an epithelial-derived carcinoma comprising: (a) introducing into the mammal a first vector comprising: i) a polynucleotide encoding a rhesus monkey HER2/neu protein; and ii) a promoter operably linked to the polynucleotide; (b) allowing a predetermined amount of time to pass; and (c) introducing into the mammal a second vector comprising: i) a polynucleotide encoding a rhesus monkey HER2/neu protein; and ii) a promoter operably linked to the polynucleotide.

In one embodiment of the method of treatment described above, the first vector is a plasmid and the second vector is an adenovirus vector. In an alternative embodiment, the first vector is an adenovirus vector and the second vector is a plasmid.

The amount of expressible DNA or transcribed RNA to be introduced into a vaccine recipient will depend partially on the strength of the promoters used and on the immunogenicity of the expressed gene product. In general, an immunologically or prophylactically effective dose of about 1 ng to 100 mg, and preferably about 10 μ g to 300 μ g of a plasmid vaccine vector is administered directly into muscle tissue. An effective dose for recombinant adenovirus is approximately 10⁶ – 10¹² particles and preferably about 10⁷–10¹¹ particles. Subcutaneous injection, intradermal introduction, impression through the skin, and other modes of administration such as intraperitoneal, intravenous, or inhalation delivery are also contemplated. It is also contemplated that booster vaccinations may be provided. Parenteral administration, such as intravenous, intramuscular, subcutaneous or other means of administration with adjuvants such as interleukin 12 protein, concurrently with or subsequent to parenteral introduction of the vaccine of this invention is also advantageous.

The vaccine vectors of this invention may be naked, i.e., unassociated with any proteins, adjuvants or other agents which impact on the recipient's immune system. In this case, it is desirable for the vaccine vectors to be in a physiologically acceptable solution, such as, but not limited to, sterile saline or sterile buffered saline. Alternatively, it may be advantageous to administer an immunostimulant, such as an adjuvant, cytokine, protein, or other carrier with the vaccines or immunogenic compositions of the present invention. Therefore, this invention includes the use of such immunostimulants in conjunction with the compositions and methods of the present invention. An immunostimulant, as used herein, refers to essentially any substance that enhances or potentiates an immune response (antibody and/or cell-mediated) to an exogenous antigen. Said immunostimulants can be administered in the form of DNA or protein. Any of a variety of immunostimulants may be employed in conjunction with the vaccines and immunogenic compositions of the present inventions, including, but not limited to: GM-CSF, IFN α , tetanus toxoid, IL12, B7.1, LFA-3 and ICAM-1. Said immunostimulants are well-known in the art. Agents which assist in the cellular uptake of DNA, such as, but not limited to calcium ion, may also be used. These agents are generally referred to as transfection facilitating reagents and pharmaceutically acceptable carriers. Those of skill in the art will be able to determine the particular immunostimulant or pharmaceutically acceptable carrier as well as the appropriate time and mode of administration.

Any of a variety of procedures may be used to clone rhHER2/neu. These methods include, but are not limited to, (1) a RACE PCR cloning technique (Frohman et al., *Proc. Natl. Acad. Sci. USA* 85: 8998-9002 (1988)). 5' and/or 3' RACE may be performed to generate a full-length cDNA sequence. This strategy involves using gene-specific oligonucleotide primers for PCR amplification of rhHER2/neu cDNA. These gene-specific

primers are designed through identification of an expressed sequence tag (EST) nucleotide sequence which has been identified by searching any number of publicly available nucleic acid and protein databases; (2) direct functional expression of the rhHER2/neu cDNA following the construction of a rhHER2/neu-containing cDNA library in an appropriate expression vector system; (3) screening an rhHER2/neu-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a labeled degenerate oligonucleotide probe designed from the amino acid sequence of the rhHER2/neu protein; (4) screening an rhHER2/neu-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the rhHER2/neu protein. This partial cDNA is obtained by the specific PCR amplification of rhHER2/neu DNA fragments through the design of degenerate oligonucleotide primers from the amino acid sequence known for other growth factor receptors which are related to the rhHER2/neu protein; (5) screening a rhHER2/neu-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA or oligonucleotide with homology to a mammalian rhHER2/neu protein. This strategy may also involve using gene-specific oligonucleotide primers for PCR amplification of rhHER2/neu cDNA identified as an EST as described above; or (6) designing 5' and 3' gene specific oligonucleotides using SEQ ID NO: 1 or SEQ ID NO:40 as a template so that either the full-length cDNA may be generated by known RACE techniques, or a portion of the coding region may be generated by these same known RACE techniques to generate and isolate a portion of the coding region to use as a probe to screen one of numerous types of cDNA and/or genomic libraries in order to isolate a full-length version of the nucleotide sequence encoding rhHER2/neu.

It is readily apparent to those skilled in the art that other types of libraries, as well as libraries constructed from other cell types or species types, may be useful for isolating a rhHER2/neu-encoding DNA or a rhHER2/neu homologue. Other types of libraries include, but are not limited to, cDNA libraries derived from other cells.

It is also readily apparent to those skilled in the art that suitable cDNA libraries may be prepared from cells or cell lines which have rhHER2/neu activity, such as various epithelial-derived cells. The selection of cells or cell lines for use in preparing a cDNA library to isolate a cDNA encoding rhHER2/neu may be done by first measuring cell-associated rhHER2/neu activity using any known assay available for such a purpose.

Preparation of cDNA libraries can be performed by standard techniques well known in the art. Well known cDNA library construction techniques can be found for example, in Sambrook et al., *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989. Complementary DNA libraries may also be obtained

from numerous commercial sources, including but not limited to Clontech Laboratories, Inc. (Palo Alto, CA) and Stratagene (La Jolla, CA).

The DNA molecules, RNA molecules, and recombinant protein of the present invention may be used to screen and measure levels of rhHER2/neu. The recombinant proteins, DNA molecules, and RNA molecules lend themselves to the formulation of kits suitable for the detection and typing of rhHER2/neu. Such a kit would comprise a compartmentalized carrier suitable to hold in close confinement at least one container. The carrier would further comprise reagents such as recombinant rhHER2/neu or anti-rhHER2/neu antibodies suitable for detecting rhHER2/neu. The carrier may also contain a means for detection such as labeled antigen or enzyme substrates or the like.

All publications mentioned herein are incorporated by reference for the purpose of describing and disclosing methodologies and materials that might be used in connection with the present invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

Having described preferred embodiments of the invention with reference to the accompanying drawings, it is to be understood that the invention is not limited to those precise embodiments, and that various changes and modifications may be effected therein by one skilled in the art without departing from the scope or spirit of the invention as defined in the appended claims.

The following examples illustrate, but do not limit the invention.

EXAMPLE 1

Isolation of the Rhesus HER2/neu cDNA by RT-PCR

Molecular procedures were performed following standard procedures well known in the art (See, e.g., Ausubel et. al. *Short Protocols in Molecular Biology*, F.M., -2nd. ed., John Wiley & Sons, (1992) and Sambrook et al., *Molecular Cloning, A Laboratory Manual*, 2nd ed., Cold Spring Harbor Laboratory Press (1989), which are hereby incorporated by reference).

HER2/neu nucleotide sequences from human, hamster, dog, and rat were aligned to identify highly conserved regions of the HER2/neu DNA. Based on the sequence comparison, oligonucleotide primers spanning the HER2/neu gene were designed for amplification of the rhesus HER2/neu cDNA by reverse transcriptase polymerase chain reaction (RT-PCR), described below. (see FIGURE 3).

Colon biopsies from two different Rhesus monkeys (*macaca mulatta*) were obtained from Dr. Willem Collignon (Biomedical Primate Research Centre (BPRC), Rijswijk, The Netherlands). RNA was extracted and purified from each colon biopsy using the UltraSPec-

II RNA isolation system (Biotecx, Houston, TX) according to the manufacturer's instructions. To isolate the rhesus HER2/neu gene, RT-PCR amplification products covering the entire HER2/neu sequence were generated from total RNA isolated from a single rhesus monkey.

To perform the reverse transcription step, total RNA samples were reverse transcribed using the Superscript One-Step RT-PCR Amplification Kit for Long Templates (Life Technologies; Carlsbad, CA) according to the manufacturer's instructions. Typically, 0.5-2.0 µg RNA were combined with the reverse transcriptase enzyme and the appropriate buffer in a 50µl reaction volume. Samples were incubated at 45 °C for 30 min, followed by a 2 minute incubation at 94 °C.

Using the resulting cDNA templates, PCR amplifications were performed using different combinations of forward and reverse primers (see FIGURE 3). PCR was carried out in a Perkin Elmer 2400 thermocycler (Perkin Elmer, Inc., Wellesley, MA). Cycling conditions consisted of 35 cycles of an initial denaturation step of 94°C for 15 sec, followed by a primer annealing step and concluding with an extension step. The primer annealing step consisted of incubation for 50 sec at a temperature ranging from (50°C -51°C), depending on the primer sequence. The extension step consisted of an incubation at 68°C for a length of time ranging from (80 sec-100 sec), depending on the expected length of the amplification product. The above 35 cycles were followed by an extensive elongation step of 7 min at 72°C.

Amplification products were gel-purified using the QIAquick PCR Purification Kit (Qiagen, Hilden, Germany) and sequenced with the same primers used for amplification. Sequencing reactions were carried out through Big Dye Terminator chemistry, using the Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA). Readings were performed using an ABI Prism 377 DNA sequencer (Applied Biosystem).

Data acquired by sequencing the different amplification products, which encompass the entire HER2/neu coding region, identified the rhesus HER2/neu sequence, disclosed herein as SEQ ID NO:1 (hereinafter "first rhesus HER2 nucleotide sequence" or "rhHER2#1," see FIGURE 1). The presence of an "R" at position 795 of SEQ ID NO:1 indicates that clones isolated from the first rhesus monkey comprised either an A or a G at that position. A nucleic acid molecule isolated from the first rhesus monkey and comprising an "A" at position 795 is designated herein SEQ ID NO:42. A nucleic acid molecule isolated from the first rhesus monkey and comprising a "G" at position 795 is designated herein SEQ ID NO:43. The single nucleotide change at position 795 of SEQ ID NO:1, based on DNA isolated from the first rhesus monkey, did not affect the resulting amino acid sequence of the HER2/neu protein, which is disclosed herein as SEQ ID NO:2 (see FIGURE 2).

Amplification products derived from the above RT-PCR reactions were cloned into either vector BlueScript ks(+) or pCRII, referred to herein as BS or CR, respectively. The resulting clones were sequenced to confirm the rhHER2/neu nucleotide sequence obtained by direct sequencing of amplification products and used to assemble the complete rhesus HER2/neu cDNA sequence.

EXAMPLE 2

Assembly of the Complete HER2/neu cDNA Sequence

A series of clones obtained from the first rhesus monkey were constructed and assembled by PCR to generate the complete rhesus HER2/neu cDNA. First, four RT-PCR amplification products spanning the 5' end of the rhesus HER2/neu gene were generated as described in EXAMPLE 1. The PCR - amplified fragments from the above clones were cloned into either BS or CR, as indicated in FIGURE 4 (Reactions 1-4). Sequence analysis of several clones confirmed that the cloned sequences were the same as sequences obtained from the RT-PCR fragments.

The overlapping amplification products described above were ligated in a 100µl PCR reaction in which the following components were combined: 0.1-1.0 pmol of each of the above fragments, Pfu polymerase (Stratagene, La Jolla, CA) and the appropriate buffer. Samples were subjected to an initial amplification cycle consisting of 30 sec at 95°C, followed by 4 min at 72°C.

The resulting ligation product was amplified again with the PmeI_SwaI_RBS_1-16 (SEQ ID NO:11) and 1895-1876 (SEQ ID NO:10) primers using Pfu polymerase and the appropriate buffer with the following thermal profile: 95°C for 30 sec, 58°C for 30 sec and 72°C for 180 sec (30 cycles). The PCR product thus obtained was gel purified and cloned into pCRII vector to generate clone #1_CR_1-1895.7(-) (in the anti-clockwise orientation). Sequence analysis of several clones confirmed the identity of the cloned sequence.

Colon RNA from the first rhesus monkey was used to generate an additional PCR fragment by RT-PCR, essentially as described above. Oligonucleotide primers used for this purpose were as follows: 1558-1583 (SEQ ID NO:12) and 2798-2776 (SEQ ID NO:13) (Reaction 6, FIGURE 4). This fragment, located in the center portion of the HER2/neu gene, was used as a template for further amplification, without cloning.

Primers were then designed to PCR-amplify this region from bp 1621 to bp 2277 (FIGURE 4, Reactions 7, SEQ ID NOs: 14, 15) and from bp 2239 to 2798 (FIGURE 4, Reaction 8, SEQ ID NOs: 16 and 13). The resulting products were cloned into the pCRII vector. In order to inactivate the tyrosine kinase activity of the protein, primers were designed to mutate amino

acid position 579 from K to A (SEQ ID NOs:15 and 16). Sequence analysis of several clones confirmed the identity of the cloned sequences.

Colon RNA from the first rhesus monkey was used to generate an additional PCR fragment by RT-PCR, essentially as described above. Oligonucleotide primers used for this purpose were as follows: 2356-2378 (SEQ ID NO:17) and 4166-4145 (SEQ ID NO:18) (FIGURE 4, Reaction 9). The resulting product was cloned into the pCRII vector. Sequence analysis confirmed the identity of the cloned sequences.

DNA fragments were PCR amplified from the three above clones using the following primers: 1621-1644 (SEQ ID NO 14) and 2277-K753-2248 (SEQ ID NO 15) with template #1_CR_1621-2277.2; 2239-K756-2248 (SEQ ID NO 16) and 2798-2776 (SEQ ID NO 13) with template #1_CR_2239-2798.4; 2356-2378 (SEQ ID NO 17) and *Sa*II_3768-3746 (SEQ ID NO 19) with template #1_CR_2356-4169.2. The three products were assembled by PCR as described above. The resulting ligation product was amplified using the following primers: 1621-1644 (SEQ ID NO:14) and *Sa*II_3768-3746 (SEQ ID NO:19) and cloned into pCRII vector in the clockwise orientation, generating clones #1-CR_1621-3768.8 (hereinafter clone 10.8) and #1-CR_1621-3768.12 (hereinafter clone 10.12) (FIGURE 4, Reactions 10). Sequencing revealed that clone 10.12 had a mutation around position 3686 in the 3' region. Similarly, clone 10.8 had a mutation around position 2666. A wild type sequence was generated by replacing a 508 bp *Bst*EII-*Sa*II fragment from clone 10.12 with the corresponding region from clone 10.8, which did not include mutations in this region. The resulting clone was named #1-CR_1621-3768.128.

A *P*mII-*X*baI fragment from clone #1_CR_1621_3768.128(+) was cloned into the *P*mII-*S*peI sites of clone #1_CR_1_1895.7(-). The resulting plasmid, which contains the entire rhesus HER2/neu coding sequence, was named #1_CR_1-3768(-). Sequence analysis confirmed the identity of the sequence.

EXAMPLE 3

Immunogens

For gene transduction and immunization studies, the rhHER2/neu coding region was excised from #1_CR_1-3768(-) by digestion with *P*meI and *Sa*II and inserted into the *E*coRV and *Sa*II sites of mammalian expression plasmid pV1J_nsA (Montgomery et al., *DNA Cell Biol.* 12(9): 777-83 (1993)), generating pV1J-rh-HER2/neu.

For adenovirus vector construction, the rhHER2/neu-encoding sequence was excised from #1_CR_1-3768(-) by digestion with *P*meI and *Sa*II and cloned into the corresponding site of the ppolyMRKAΔ5ΔE1 shuttle plasmid, generating pMRKAΔ5ΔE1-

rhHER2/neu. Shuttle vector pMRKAd5ΔE1 contains Ad5 sequences from b.p. 1 to b.p. 450 and from b.p. 3511 to b.p. 5798 with an expression cassette containing human cytomegalovirus (HCMV) promoter (without intron A) and bovine growth hormone polyadenylation signal. The plasmid was recombined with the adenoviral backbone vector pMRKAd5HVO, which contains all Ad5 sequences except those encompassing the E1 and E3 regions, using *E. coli* BJ5183 cells (Chartier et al., *J. Virol.* 70: 4805-10 (1996)).

For vector production, pMRKAd5-rhHER2/neu was linearized by digestion with *PacI* and transfected in PerC.6 cells using Lipofectamine (Life Technologies, Rockville, MD). 5-6 viral passages were performed to amplify viral titer and a large viral amplification was carried out with a final production of 1.3×10^{12} physical particles (pp). No genome rearrangements were detectable in the viral genome purified from the amplified vector, as indicated by restriction fragment length polymorphism (RFLP) analysis. The expected DNA fragments were observed both in the viral genome and in the control pMRKAd5-HER2/neu plasmid, restricted in parallel.

EXAMPLE 4

Isolation of HER2/neu-encoding DNA from a Second Rhesus Monkey

A similar sequencing analysis of RT-PCR products was performed using colon RNA from a second rhesus monkey (see EXAMPLE 1). Data acquired by sequencing many different amplification products encompassing the whole gene identified a second rhesus HER2/neu sequence, disclosed herein as SEQ ID NO:40, (hereinafter "second rhesus HER2 nucleotide sequence" or "rhHER2#2," see FIGURE 5), with the deduced amino acid sequence disclosed herein as SEQ ID NO:41 (hereinafter "second rhesus HER2 amino acid sequence," see FIGURE 6).

As in EXAMPLE 1, amplification products were generated by RT-PCR of total colon RNA from the second rhesus monkey using primers spanning the HER2/neu gene (see FIGURE 3). The resulting amplification products were gel-purified and sequenced. Additionally, these products were cloned into either the BS or the CR vector. DNA sequencing analysis of the resulting clones confirmed the rhHER2/neu nucleotide sequences obtained by direct sequencing of amplification products.

Eight differences were detected between rhHER2#1 and rhHER2#2 (for details, see FIGURE 7). Five of these mutations introduce an amino acid change in the protein as compared to the first rhesus HER2 amino acid sequence (SEQ ID NO:2). Of note, three of these mutations do not produce amino acid changes in the rhHER2#2 protein as compared with the rhHER2#1 protein.

EXAMPLE 5

Immunization of Rhesus Macaques with rhHER2/neu

In order to assess the efficiency of immunization of Rhesus macaques (*Macaca mulatta*) with the rhesus homologues of the human tumor antigen HER2/neu, which is expressed in colorectal carcinomas, immunization studies were performed at the Biomedical Primate Research Centre (BPRC), Rijswijk (The Netherlands). The studies were designed to evaluate both B and T cell responses to immunization with the rhesus HER2/neu antigen.

In a first study, one group of monkeys (4 rhesus monkeys total; 2 males and 2 females) were immunized with a plasmid DNA vector or an adenovirus vector expressing the rhesus homologue of the human tumor antigen HER2/neu (pV1J-rhHER2). For priming, animals were vaccinated intramuscularly (i.m.) with plasmid DNA at weeks 0, 4, 8, 12, and 16, by injection of DNA followed by electrical stimulation. The DNA was injected as a 1 ml solution (split over 2 sites with 0.5 ml/site) containing 5 mg pV1J-rhHER2 plasmid DNA for animals weighing 2-5 kilos. Animals are injected under anesthesia (mixture of ketamine/xylazine).

For electrostimulation, 2 trains of 100 square bipolar pulses (1 sec each), were delivered every other second for a total treatment time of 3 sec. The pulse length was 2 msec/phase with a pulse frequency and amplitude of 100 Hz and 100 mA (constant current mode), respectively.

The same group of animals was boosted by i.m. injection of Adenovirus 5 (Ad5) expressing rhesus HER2/neu. A $\Delta E1-\Delta E3$, "first generation" Adenovirus (P2 level) was used. A total amount of 10^{11} viral particles (vp) were injected at week 24 and 28.

A further boosting was carried out by i.m. injection of 10^{11} viral particles (vp) of Adenovirus 24 (Ad24) expressing rhesus HER2/neu at weeks 36 and 40. Ad24 was chosen because neutralizing antibodies induced by Ad5 injection do not interfere with Ad24 infection.

To measure the immune response to HER2/neu induced by the above immunization protocol, blood samples were collected every four weeks for a total duration of one year. The HER2-specific cell mediated immune response was measured by IFN γ ELISPOT assay. The number of IFN- γ -secreting anti-rhesus HER2 T cells was determined by ELISPOT on PBMC using pools of peptides. Three hundred and eleven peptides, each 15 amino acids long, overlapping by 11 residues and spanning the entire rhesus protein sequence, were combined into eleven pools indicated with alphabetical letters from A to K (from N- to C-terminus). The frequency of IFN- γ producing PBMC was calculated as the average value of

spots derived from duplicates at two different cell concentrations. Values were expressed as the number of spot forming colonies (SFC)/ 10^6 total PBMC, minus the background values determined in the absence of peptides (typically less than 10 SFC/ 10^6 total spleen cells). Calculated results indicate that all four monkeys showed a detectable cell-mediated response, as measured by IFN- γ ELISPOT.

Reactivity was confirmed and typed by IFN- γ intracellular staining (ICS), which measured the frequency of CD4⁺ or CD8⁺ T-cell secreting IFN- γ . CD3⁺ lymphocytes were collected by simultaneously gating on CD3⁺ events and small lymphocytes. Values higher than 0.1 % were considered positive. A positive value of 0.19 (CD8+) was obtained for monkey RI504 for pool J. No detectable anti-rhHER2 antibodies titres (> 200) were detected.

In summary, i.m. injection of plasmid DNA expressing rhesus HER2/neu was effective in breaking tolerance and inducing a detectable cell-mediated immune response against rhHER2/neu in rhesus monkeys

EXAMPLE 6

Immunization of Rhesus Macaques with Rhesus Homologs of Human Tumor-Associated Antigens

A second series of immunization studies were performed at the Biomedical Primate Research Centre (BPRC), Rijswijk (The Netherlands) in order to assess the efficiency of immunization of Rhesus macaques (*macaca mulatta*) with rhesus homologues of the human tumor antigens HER2/neu, Ep-CAM and CEA, which are all expressed in colorectal carcinomas. Protocols were designed to evaluate both B and T cell responses to these tumor antigens in combination.

In this study, a second group of 4 rhesus monkeys (2 males and 2 females) were immunized with a mixture of three plasmid DNA vectors expressing the rhesus homologues of human tumor antigens Ep-CAM (pV1J-rhHER2), CEA (pV1J-rhCEA), and HER2/neu (pV1J-rhEpCAM).

Animals were primed by i.m. injection of plasmid DNA at weeks 0, 4, 8, 12, and 16, followed by electrostimulation. The DNA injection consisted of a 1 ml solution (split over 2 sites with 0.5 ml/site) containing 6 mg plasmid DNA (2 mg for each of the three TAAs) for animals weighing 2-5 kilos. Animals were injected under anesthesia (mixture of ketamine/xylazine).

For electrostimulation, 2 trains of 100 square bipolar pulses (1 sec each), were delivered every other second for a total treatment time of 3 sec. The pulse length was 2

msec/phase with a pulse frequency and amplitude of 100 Hz and 100 mA (constant current mode), respectively.

The same group of animals was boosted by injection of a mixture of three Ad5-expressing rhesus HER2/neu (Ad5-rhHER2), rhesus CEA (Ad5-rhCEA) and rhesus EpCAM (Ad5-rhEpCAM). A total amount of 3×10^{11} viral particles (vp), were injected i.m. at weeks 23 and 27 (1×10^{11} vp for each of the three viruses).

A further boosting was carried out by i.m. injection of a mixture of three Ad24-expressing rhesus HER2/neu (Ad24-rhHER2), rhesus CEA (Ad24-rhCEA) and rhesus EpCAM (Ad24-rhEpCAM). A total amount of 3×10^{11} viral particles (vp), were injected i.m. at weeks 36 and 40 (1×10^{11} vp for each of the three viruses).

To measure the immune response to HER2/neu using the above immunization protocol, blood samples were collected every four weeks for a total duration of one year. The cell mediated immune response was measured by IFN- γ ELISPOT and intracellular staining, whereas the humoral response was measured by ELISA.

Monkeys RI449 and RI519 showed a detectable HER2-specific cell-mediated response, as measured by IFN- γ ELISPOT analysis. A similar analysis did not detect any response against rhCEA and rhEpCAM. No detectable anti-rhHER2 antibodies titres (> 200) were detected.

In a third study, 4 rhesus monkeys were immunized with a mixture of Ad5-rhHER2, Ad5-rhCEA and Ad5-rhEpCAM by i.m. injection of Ad5 derivatives at weeks 0, 2 and 4. A 1 ml solution (split over 2 sites with 0.5 ml/site) containing 3×10^{11} vp (10^{11} for each of the three Ad5 virus) was administered to animals weighing 2-5 kilos, under anesthesia (mixture of ketamine/xylazine).

The same group of animals was boosted at weeks 24, 26 and 28 by i.m. injection of a mixture of Ad24-rhHER2, Ad24-rhCEA and Ad24-rhEpCAM (a total amount of 3×10^{11} vp, 10^{11} vp for each of the three viruses). The cell mediated response was measured by IFN γ ELISPOT assay. For monkeys RI514 and RI496, reactivity was typed by IFN- γ intracellular staining. Three out of four monkeys showed a detectable response. In addition, anti-rhHER2 antibody titres ranging from 200 to 500 were detected in the three monkeys where a cell-mediated response was measured.

This immunization protocol was also effective in breaking tolerance and inducing anti-rhCEA cell-mediated and humoral immune responses. Monkey RI514 showed a measurable cell mediated response by IFN- γ ELISPOT analysis. Intracellular staining confirmed this response. The same monkey also showed anti-rhCEA antibodies titres ranging from 500 to 1000. By contrast, a similar analysis did not detect any response against rhEpCAM.

In summary, the immunization protocol discussed above was effective in inducing a specific immune response against rhHER2/neu and rhCEA in rhesus monkeys.

WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising a sequence of nucleotides that encodes a rhesus monkey HER2/neu protein as set forth in SEQ ID NO:2 or SEQ ID NO:41.
2. The isolated nucleic acid molecule of claim 1 wherein the nucleic acid is DNA.
3. The isolated nucleic acid molecule of claim 1 wherein the sequence of nucleotides comprises the sequence of nucleotides set forth in SEQ ID NO:1, SEQ ID NO:40, SEQ ID NO:42, or SEQ ID NO:43.
4. A vector comprising the nucleic acid molecule of claim 1.
5. A host cell comprising the vector of claim 4.
6. A process for expressing a rhesus HER2/neu protein in a recombinant host cell, comprising:
 - (a) introducing a vector comprising the nucleic acid of claim 1 into a suitable host cell; and,
 - (b) culturing the host cell under conditions which allow expression of said rhesus HER2/neu protein.
7. An isolated and purified rhesus HER2/neu polypeptide comprising a sequence of amino acids as set forth in SEQ ID NO:2 or SEQ ID NO:41.
8. A method of preventing or treating cancer comprising administering to a mammal a vaccine vector comprising an isolated nucleic acid molecule, the isolated nucleic acid molecule comprising a sequence of nucleotides that encodes a rhesus monkey HER2/neu protein as set forth in SEQ ID NO:2 or SEQ ID NO:41.
9. A method according to claim 8 wherein the mammal is human.
10. A method according to claim 8 wherein the vector is an adenovirus vector or a plasmid vector.

11. A method according to claim 8 wherein the vector is a plasmid vaccine vector, which comprises a plasmid portion and an expressible cassette comprising

- (a) a polynucleotide encoding a rhesus monkey HER2/neu protein; and
- (b) a promoter operably linked to the polynucleotide.

12. An adenovirus vaccine vector comprising an adenoviral genome with a deletion in the E1 region, and an insert in the E1 region, wherein the insert comprises an expression cassette comprising:

- (a) a polynucleotide encoding a rhesus monkey HER2/neu protein; and
- (b) a promoter operably linked to the polynucleotide.

13. A vaccine plasmid comprising a plasmid portion and an expression cassette portion, the expression cassette portion comprising:

- (a) a polynucleotide encoding a rhesus monkey HER2/neu protein; and
- (b) a promoter operably linked to the polynucleotide.

14. A method of protecting a mammal from cancer comprising:

- (a) introducing into the mammal a first vector comprising:
 - (i) a polynucleotide encoding a rhesus monkey HER2/neu protein;

and

- (ii) a promoter operably linked to the polynucleotide;
- (b) allowing a predetermined amount of time to pass; and
- (c) introducing into the mammal a second vector comprising:
 - (i) a polynucleotide encoding a rhesus monkey HER2/neu protein;

and

- (ii) a promoter operably linked to the polynucleotide.

15. A method according to claim 14 wherein the first vector is a plasmid and the second vector is an adenovirus vector.

16. A method according to claim 14 wherein the first vector is an adenovirus vector and the second vector is a plasmid.

17. A method of treating a mammal suffering from an epithelial-derived carcinoma comprising:

(a) introducing into the mammal a first vector comprising:

(i) a polynucleotide encoding a rhesus monkey HER2/neu protein;

and

(ii) a promoter operably linked to the polynucleotide;

(b) allowing a predetermined amount of time to pass; and

(c) introducing into the mammal a second vector comprising:

(i) a polynucleotide encoding a rhesus monkey HER2/neu protein;

and

(ii) a promoter operably linked to the polynucleotide.

18. A method according to claim 17 wherein the first vector is a plasmid and the second vector is an adenovirus vector.

19. A method according to claim 17 wherein the first vector is an adenovirus vector and the second vector is a plasmid.

20. A method according to claim 17 wherein the first and second vectors are adenovirus vectors.

1/9

Nucleotide Sequence of First Rhesus HER2/Neu

```

1  ATGGAGCTGG CGGCCTGGTA CCGCTGGGGG CTCCTCCTCG CCCTCTTGCC CCCC GGAGCT
61  GCGGGCACCC AAGTGTGCAC CGGCACAGAC ATGAAGCTGC GGCTCCCTGC CAGTCCCGAG
121  ACCCACCTGG ACATGCTCCG CCACCTCTAC CAGGGCTGCC AGGTGGTGCA GGGTAACCTG
181  GAACTCACCT ACCTGCCCAC CAATGCCAGC CTCTCCTTCC TGCAGGATAT CCAGGAGGTG
241  CAGGGCTACG TGCTCATCGC TCACAACCAA GTGAGGCAGG TCCCACTGCA GAGGCTGCGG
301  ATTGTGCGAG GCACCCAGCT CTTTGAGGAC AACTATGCCC TGGCCGTGCT AGACAATGGA
361  GACCTGCTGA ACAATACCAC CCCTGTCACA GGGGCCCTCC CAGGAGGCCT GCGGGAGCTG
421  CAGCTTCGAA GCCTCACAGA GATCTTGAAA GGAGGGGTCT TGATCCAGCG GAACCCCCAG
481  CTCTGCTACC AGGACACGAT TTTGTGGAAG GACATCTTCC ATAAGAACAA CCAGCTGGCT
541  CTCACACTGA TCGACACCAA CCGCTCTCGG GCCTGCCACC CCTGTTCTCC AGTGTGTAAG
601  GGCTCCCGCT GCTGGGGAGA GAGTTCTGAG GATTGTCAGA GCCTGACGCG CACTGTCTGT
661  GCCGGTGGCT GTGCCCCGCTG CAAGGGGCCA CTGCCCACTG ACTGCTGCCA TGAGCAGTGT
721  GCTGCCGGCT GCACGGGCCC CAAGCACTCT GACTGCCTGG CCTGCCTCCA CTTCAACCAC
781  AGCGGCATCT GTGARCTGCA CTGCCAGCC CTGGTCACCT ACAACACAGA CACCTTTGAG
841  TCCATGCCCA ACCCCGAGGG CCGGTATACA TTCGGCGCCA GCTGTGTGAC TGCCTGTCCC
901  TACAACCTACC TTTCTACGGA CGTGGGATCC TGCACCCTCG TCTGCCCCCT GCACAACCAA
961  GAGGTGACAG CGGAGGACGG AACACAGCGA TGTGAGAAGT GCAGCAAGCC CTGTGCCCGA
1021  GTGTGCTATG GTCTGGGCAT GGAGCACTTG CGAGAGGTGA GGGCGGTGAC CAGTGCCAAT
1081  ATCCAGGAGT TTGCTGGCTG CAAGAAGATC TTTGGGAGCT TGGCATTCTT GCCAGAGAGC
1141  TTTGATGGCG ACCCAGCCTC CAACACCGCC CCGCTTCAGC CGGAGCAGCT CCGAGTGTTC
1201  GAGACTCTGG AAGAGATCAC AGGTTACCTA TACATCTCAG CATGGCCAGA CAGCCTGCCT
1261  GACCTTAGCG TCCTCCAGAA CCTGCAAGTA ATCCGGGGAC GAATTCTGCA CAATGGCGCC
1321  TACTCACTGA CCCTGCAAGG GCTGGGCATC AGCTGGCTGG GGCTGCGCTC GCTGAGGGAA
1381  CTGGGCAGTG GACTGGCCCT CATCCACCAT AACACCCGCC TCTGCTTTGT GCACACGGTG
1441  CCCTGGGACC AGCTCTTCCG GAACCCGCAC CAAGCCCTGC TCCACACTGC CAACCGGCCA
1501  GAGGACGAGT GTGTGGGCGA GGGCCTGGCC TGCCACCAGC TGTGCGCCCG AGGGCACTGC
1561  TGGGGTCCAG GGCCACCCA GTGTGTCAAC TGCAGCCAGT TCCTTCGGGG CCAGGAGTGC
1621  GTGGAGGAAT GCCGAGTACT GCAGGGGCTC CCCAGGGAGT ATGTGAATGC CAGACACTGT
1681  TTGCCGTGCC ACCCTGAGTG TCAGCCCCAG AATGGCTCAG TGACATGTTT TGGACCGGAG
1741  GCTGACCAGT GTGTGGCCTG TGCCCACTAT AAGGACCCTC CCTTCTGCGT GGCCCGCTGC
1801  CCCAGCGGTG TGAAACCTGA CCTCTCCTAC ATGCCCATCT GGAAGTTTCC AGATGAGGAG
1861  GGCACGTGCC AGTCTTGCCC CATCAACTGC ACCCACTCCT GTGTGGACCT GGATGACAAG
1921  GGCTGCCCCG CCGAGCAGAG AGCCAGCCCT CTGACGTCCA TCATCTCTGC TGTGGTGGGC
1981  ATTCTGCTGG TCGTGGTCTT GGGGGTGGTC TTTGGAATCC TCATCAAGCG ACGGCAGCAG
2041  AAGATCCGGA AGTACACGAT GCGGAGGCTG CTGCAGGAAA CGGAGCTGGT GGAGCCACTG
2101  ACACCGAGTG GAGCGATGCC CAACCAGGCG CAGATGCGGA TCCTGAAAGA GACGGAGCTG
2161  AGGAAGGTGA AGGTGCTTGG ATCTGGAGCT TTTGGCACAG TCTACAAGGG CATCTGGATC
2221  CCTGATGGGG AGAATGTGAA AATTCCAGTG GCCATCAAAG TGTTGAGGGA AAACACATCC

```

FIG. 1A

2/9

2281 CCCAAAGCCA ACAAAGAAAT CTTAGACGAA GCATATGTGA TGGCTGGTGT GGGCTCCCCA
2341 TATGTCTCCC GCCTCCTGGG CATCTGCCTG ACATCCACGG TGCAGCTGGT GACACAGCTT
2401 ATGCCCTATG GCTGCCTCTT AGACCATGTC CGAGAAAACC GCGGACGCCT GGGCTCCCAG
2461 GACCTGCTGA ACTGGTGTAT GCAGATTGCC AAGGGGATGA GCTACCTGGA GGATGTGCGG
2521 CTCGTACACA GGGACTTGGC TGCTCGGAAC GTGCTGGTCA AGAGTCCCAA CCATGTCAAA
2581 ATTACAGACT TTGGGCTGGC TCGGCTGCTG GACATTGACG AGACAGAGTA CCATGCAGAT
2641 GGGGGCAAGG TGCCCATCAA GTGGATGGCG CTGGAGTCCA TTCTCCGACG GCGGTTTACC
2701 CACCAGAGTG ATGTGTGGAG TTATGGTGTG ACTGTGTGGG AGCTGATGAC TTTTGGGGCC
2761 AAACCTTACG ATGGGATCCC AGCCCGGGAG ATCCCTGACC TGCTGGAAAA GGGGGAGCGG
2821 CTGCCCCAGC CCCCCTCTG CACCATTGAT GTCTACATGA TCATGGTCAA ATGTTGGATG
2881 ATTGACTCTG AATGTCGGCC GAGATTCCGG GAGTTGGTGT CGGAATTCTC CCGCATGGCC
2941 AGGGACCCCC AGCGCTTTGT GGTCATCCAG AATGAGGACT TGGGCCCAGC CAGTCCCTTG
3001 GACAGCACCT TCTACCGCTC ACTGCTGGAG GACGATGACA TGGGGGACCT GGTGGATGCT
3061 GAGGAGTATC TGGTACCCCA GCAGGGCTTC TTCTGTCCAG ACCCTGCCCC GGGCACTGGG
3121 GGCATGGTCC ACCACAGGCA CCGCAGCTCA TCTACCAGGA GTGGCGGTGG GGACCTGACG
3181 CTAGGGCTGG AGCCCTCTGA AGAGGAGGCC CCCAGGTCTC CACGGGCACC CTCCGAAGGG
3241 ACTGGCTCTG ATGTATTTGA TGGTGACCTA GGAATGGGGG CAGCCAAGGG GCTGCAAAGC
3301 CTCCCCGCAC ATGACCCAG CCCTCTACAG CGGTACAGTG AGGACCCAC GGTACCCCTG
3361 CTTTCTGAGA CTGACGGCTA CGTTGCCCC CTGACCTGCA GTCCCCAGCC CGAATATGTG
3421 AACCAGCCAG ATGTTTCGGC ACAGCCCCCT TCGCCCCAAG AGGGCCCTCT GTCTCCTGCC
3481 CGACCTACTG GTGCCACTCT GGAAAGGCCC AAGACTCTCT CCCCAGGGAA GAATGGGGTT
3541 GTCAAAGACG TTTTTCCTT TGGGGGTGCT GTGGAGAACC CCGAGTACTT GGCACCCCGG
3601 GGAGGAGCTG CCCCTCAGCC CCACCTTCCT CCTGCCTTCA GCCCAGCCTT CGACAACCTC
3661 TATTACTGGG ACCAGGACCC ATCAGAGCGG GGGGCTCCAC CTAGCACCTT CAAAGGGACA
3721 CCTACGGCAG AGAACCAGG GTACCTGGGT CTGGACGTGC CAGTGTGA (SEQ ID NO:1)

FIG. 1B

3/9

Predicted Amino Acid Sequence of First Rhesus
Her2/Neu Protein (SEQ ID NO:2)

```
1 MELAAWYRWG LLLALLPPGA AGTQVCTGTD MKLRLPASPE THLDMLRHLY QGCQVVQGNL
61 ELTYLPTNAS LSFLQDIQEV QGYVLIAHNQ VRQVPLQRLR IVRGTQLFED NYALAVLDNG
121 DLLNNTTPVT GASPGLREL QLRSLTEILK GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA
181 LTLIDTNRSR ACHPCSPVCK GSRCWGESSE DCQSLTRTVC AGGCARCKGP LPTDCCHEQC
241 AAGCTGPKHS DCLACLHFNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
301 YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL REVRAVTSAN
361 IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLRVF ETLEEITGYL YISAWPDSL P
421 DLSVLQNLQV IRGRILHNGA YSLTLQGLGI SWLGLRSLRE LGSGLALIIH NTRLCFVHTV
481 PWDQLFRNPH QALLHTANRP EDECVGEGLA CHQLCARGHC WPGPPTQCVN CSQFLRGQEC
541 VEECRVLQGL PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC
601 PSGVKPDLSY MPIWKFPDEE GTCQSCPINC THSCVDLDDK GCPAEQRASP LTSIISAVVG
661 ILLVVVLGVV FGILIKRRQQ KIRKYTMRR LQETELVEPL TPGAMPNQA QMRILKETEL
721 RKVKVLGSGA FGTVYKGIWI PDGENVKIPV AIKVLRENTS PKANKEILDE AYVMAGVGSP
781 YVSRLLGICL TSTVQLVTQL MPYGCLLDHV RENRGRLGSQ DLLNWC MQIA KGMSYLEDVR
841 LVHRDLAARN VLVKSPNHVK ITDFGLARLL DIDETEHAD GGKVPIKWMA LESILRRRFT
901 HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID VYMIMVKCWM
961 IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL DSTFYRSLLE DDDMGDLVDA
1021 EEYLVPQQGF FCPDPAPGTG GMVHHRHRSS STRSGGGDLT LGLEPSEEEA PRSPRAPSEG
1081 TGSDVFDGDL GMGAAKGLQS LPAHDPSPLQ RYSEDPTVPL PSETDGYVAP LTCSPQPEYV
1141 NQPDVRPQPP SPQEGPLSPA RPTGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLAPR
1201 GGAAPQPHLP PAFSPAFDNL YYWDQDP SER GAPPSTFKGT PTAENPEYLG LDVPV*
```

FIG.2

4/9

Oligonucleotide Primers Spanning Rhesus Her2/neu Gene

Forward	Sequence	Reverse	Sequence
(-30)-(-10)	AGCCATGGGGGGGAGGCCCA (SEQ ID NO:3)	96-79	CTTCATGTCGTGCGCGT (SEQ ID NO:20)
(-22)-(-1)	GGCGGAGCGCCAGCTGAGCACC (SEQ ID NO:21)	431-409	CTTCGAGCTGAGCTCCCGCAG (SEQ ID NO:22)
1-25	ATGGAGCTGGCGGCTTGTGCGCGT (SEQ ID NO:23)	812-787	AGCGCTGGGCGAGTGGAGCTCAGAGT (SEQ ID NO:4)
79-96	ACCGGCACAGACATGAAG (SEQ ID NO:24)	1115-1096	CCAAAGATCTCTTGCAGCC (SEQ ID NO:6)
409-431	CTGGCGGAGCTGAGCTTCGAG (SEQ ID NO:5)	1370-1352	GAGCGCAGCCCGAGCCAGC (SEQ ID NO:8)
787-812	ATCTGTGAGCTGCACTCGCCAGCCCT (SEQ ID NO:7)	1583-1558	CACCTGGCTGGGCGCTGGACCCAGCA (SEQ ID NO:25)
1096-1115	GGCTGCAGAGATCTTTGG (SEQ ID NO:9)	1885-1876	TGGGTCCAGTTGATGGGGCA (SEQ ID NO:10)
1352-1370	GTGGCTGGGCTGCGCTC (SEQ ID NO:27)	2183-2161	GATCCAGCAGCTTCACCTTCCT (SEQ ID NO:26)
1558-1583	TGCTGGGTCGAGGCGCCACCCAGTC (SEQ ID NO:12)	2222-2200	GGGATCCAGATGCCCTTGTAGAC (SEQ ID NO:28)
1876-1895	TGCCCCATGACATGCACCCA (SEQ ID NO:29)	2277-1753A-2239	TCGTGTTTCCCTCAGACGCGGATGCCACTCGAAATTT (SEQ ID NO:15)
2161-2183	AGGAGGTGAAGTGCTTGGATC (SEQ ID NO:31)	2378-2356	GTGGATGTCAGGAGATGCCAG (SEQ ID NO:30)
2200-2222	GCTACAGGGCATCTGGATCCC (SEQ ID NO:33)	2768-2743	TAAAGTTTGGGCGCCAAAAGTCATCAG (SEQ ID NO:32)
2239-1753A 2277	AAAAATCCAGTGGCCATGCGCGTGTGAGGGAACACA (SEQ ID NO:16)	2798-2776	TCAGGGATCTCCGCGCTGGGAT (SEQ ID NO:13)
2356-2378	CTGGGATCTGCCTGACATCCAC (SEQ ID NO:17)	3410-3388	GGCTGGCGGCTGCAGGTCAGGGG (SEQ ID NO:34)
2743-2768	CTGATGACTTTTGGGGCCAAACCTTA (SEQ ID NO:35)	Sal I 3768-3746	GGCGTGGACTTTACATGGCAGCTCCAGACCCA (SEQ ID NO:19)
2776-2798	ATCCAGCCCGGAGATCCCTCA (SEQ ID NO:37)	3791-3770	TTCTGGGAGCTTGGCGTCTGG (SEQ ID NO:36)
3388-3410 ²	CCCCTGACCTGCAGCCCCCAGCC (SEQ ID NO:39)	3885-3869	TGGCAGCTTCCCGCTGCA (SEQ ID NO:38)
1621-1644	GTGGAGCAATGCCCGAGTACTGCAG (SEQ ID NO:14)	4166-4145	GGTTTCAGGAGAGTCTTGAA (SEQ ID NO:18)
Phos L_Swa L_RBS_1-16	CCAGTTTAAACATTTAAATGCGGCCACCATGGAGCTGGC		
	GGCCCT (SEQ ID NO:11)		

FIG.3

5/9

RT-PCR Primers and Clones Used to Construct Full-Length rhHER2/neu Clone.

Rxn.#	Oligonucleotide Primer		Clone
	Forward	Reverse	
1	AGCCATGGGCGGAGCGCA (SEQ ID NO:3)	AGGCTGGCAGTCGAGCTCACAGAT (SEQ ID NO:4)	#1_BS_(-30)-812.A1
2	CTGCGGAGCTGCACCTTGAAG (SEQ ID NO:5)	CCAAAGATCTTCTTGCAGCC (SEQ ID NO:6)	#1_CR_409_1115.2
3	ATCTGTGAGCTGCACCTGCCAGCCCT (SEQ ID NO:7)	GAGCGAGCCCCAGCCAGC (SEQ ID NO:8)	#1_CR_787_1370.10
4	GGCTGCAAGAAGATCTTGG (SEQ ID NO:9)	TGGTCCAGTTGATGGGCA (SEQ ID NO:10)	#1_BS_1096_1895.11
5	CCAGTTTAAACATTTAAATGCCGCCACCATGGAGCTGGCGCCT (SEQ ID NO:11)	TGGTCCAGTTGATGGGCA (SEQ ID NO:10)	#1_CR_1-1895.7(-)
6	TGCTGGGTCCAGGGCCACCCAGTG (SEQ ID NO:12)	TCAGGATCTCCCGGCTGGGAT (SEQ ID NO:13)	Not Cloned (1558-2798)
7	GTTGAGGAATGCCGAGTACTGCAG (SEQ ID NO:14)	TGTGTTTTCCCTCAACACGGCGATGCCACCTGGAAATTT (SEQ ID NO:15)	#1_CR_1621-2277.2
8	AAAATTCAGTGGCCATGCCCGTGTGAGGGAACAC A (SEQ ID NO:16)	TCAGGATCTCCCGGCTGGGAT (SEQ ID NO:13)	#1_CR_2239-2798.4
9	CTGGCATCTGCCATGACATCCAC (SEQ ID NO:17)	GGTTTCAGGACAGCTCTCGAA (SEQ ID NO:18)	#1_CR_2356-4166.2
10	GTTGAGGAATGCCGAGTACTGCAG (SEQ ID NO:14)	GCCGTCGACTTTACATGGACAGTCCAGACCCA (SEQ ID NO:19)	#1_CR_1621-3768.8(+)
10	GTTGAGGAATGCCGAGTACTGCAG (SEQ ID NO:14)	GCCGTCGACTTTACATGGACAGTCCAGACCCA (SEQ ID NO:19)	#1_CR_1621-3768.12(+)

FIG.4

6/9

Nucleotide Sequence of Second Rhesus HER2/Neu

```

1  ATGGAGCTGG CGGCCTGGTA CCGCTGGGGG CTCCTCCTCG CCCTCTTGCC CCCC GGAGCT
61  GCGGGCACCC AAGTGTGCAC CGGCACAGAC ATGAAGCTGC GGCTCCCTGC CAGTCCCGAG
121 ACCCACCTGG ACATGCTCCG CCACCTCTAC CAGGGCTGCC AGGTGGTGCA GGGTAACCTG
181 GAACTCACCT ACCTGCCCAC CAATGCCAGC CTCTCCTTCC TGCAGGATAT CCAGGAGGTG
241 CAGGGCTACG TGCTCATCGC TCACAACCAA GTGAGGCAGG TCCCACTGCA GAGGCTGCGG
301 ATTGTGCGAG GCACCCAGCT CTTTGAGGAC AACTATGCCC TGGCCGTGCT AGACAATGGA
361 GACCCGCTGA ACAATACCAC CCCTGTCACA GGGGCCTCCC CAGGAGGCCT GCGGGAGCTG
421 CAGCTTCGAA GCCTCACAGA GATCTTGAAA GGAGGGGTCT TGATCCAGCG GAACCCCGAG
481 CTCTGCTACC AGGACACGAT TTTGTGGAAG GACATCTTCC ATAAGAACAA CCAGCTGGCT
541 CTCACACTGA TCGACACCAA CCGCTCTCGG GCCTGCCACC CCTGTTCTCC AGTGTGTAAG
601 GGCTCCCGCT GCTGGGGAGA GAGTTCTGAG GATTGTCAGA GCCTGACGCG CACTGTCTGT
661 GCCGGTGGCT GTGCCCCTG CAAGGGGCCA CTGCCCACTG ACTGCTGCCA TGAGCAGTGT
721 GCTGCCGGCT GCACGGGCCC CAAGCACTCT GACTGCCTGG CCTGCCTCCA CTTCAACCAC
781 AGCGGCATCT GTGARCTGCA CTGCCAGCC CTGGTCACCT ACAACACAGA CACCTTTGAG
841 TCCATGCCCA ACCCGAGGG CCGGTATACA TTCGGCGCCA GCTGTGTGAC TGCCTGTCCC
901 TACAACCTACC TTTCTACGGA CGTGGGATCC TGCACCCTCG TCTGCCCCCT GCACAACCAA
961 GAGGTGACAG CGGAGGACGG AACACAGCGA TGTGAGAAGT GCAGCAAGCC CTGTGCCCGA
1021 GTGTGCTATG GTCTGGGCAT GGAGCACTTG CGAGAGGTGA GGGCGGTAC CAGTGCCAAT
1081 ATCCAGGAGT TTGCTGGCTG CAAGAAGATC TTTGGGAGYT TGGCATTCTT GCCAGAGAGC
1141 TTTGATGGCG ACCCAGCCTC CAACACCGCC CCGCTTCAGC CGGAGCAGCT CCGAGTGTTC
1201 GAGACTCTGG AAGAGATCAC AGGTTACCTA TACATCTCAG CATGGCCAGA CAGCCTGCCT
1261 GACCTTAGCG TCCTCCAGAA CCTGCAAGTA ATCCGGGGAC GAATTCTGCA CAATGGCGCC
1321 TACTCACTGA CCCTGCAAGG GCTGGGCATC AGCTGGCTGG GGCTGCGCTC GCTGAGGGAA
1381 CTGGGCAGTG GACTGGCCCT CATCCACCAT AACACCCGCC TCTGCTTTGT GCACACGGTG
1441 CCCTGGGACC AGCTCTTCCG GAACCCGCAC CAAGCCCTGC TCCCACTGC CAACCGGCCA
1501 GAGGACGAGT GTGTGGGCGA GGGCCTGGCC TGCCACCAGC TGTGCGCCCR AGGGCACTGC
1561 TGGGGTCCAG GGCCACCCA GTGTGTCAAC TGCAGCCAGT TCCTTCGGGG CCAGGAGTGC
1621 GTGGAGGAAT GCCGAGTACT GCAGGGGCTC CCCAGGGAGT ATGTGAATGC CAGACACTGT
1681 TTGCCGTGCC ACCCTGAGTG TCAGCCCCAG AATGGCTCAG TGACATGTTT TGGACCGGAG
1741 GCTGACCAGT GTGTGGCCTG TGCCCACTAT AAGGACCCTC CCTTCTGCGT GGCCCGCTGC
1801 CCCAGCGGTG TGAAACCTGA CCTCTCCTAC ATGCCATCT GGAAGTTTCC AGATGAGGAG
1861 GGCACGTGCC AGCCTTGCCC CATCAACTGC ACCCACTCCT GTGTGGACCT GGATGACAAG
1921 GGCTGCCCCG CCGAGCAGAR AGCCAGCCCT CTGACGTCCA TCATCTCTGC TGTGGTGGGC
1981 ATTCTGCTGG TCGTGGTCTT GGGGGTGGTC TTTGGAATCC TCATCAAGCG ACGGCAGCAG
2041 AAGATCCGGA AGTACACGAT GCGGAGGCTG CTGCAGGAAA CGGAGCTGGT GGAGCCACTG
2101 ACACCGAGTG GAGCGATGCC CAACCAGGCG CAGATGCGGA TCCTGAAAGA GACGGAGCTG
2161 AGGAAGGTGA AGGTGCTTGG ATCTGGAGCT TTTGGCACAG TCTACAAGGG CATCTGGATC
2221 CCTGATGGGG AGAATGTGAA AATTCCAGTG GCCATCAAAG TGTTGAGGGA AAACACATCC

```

FIG. 5A

7/9

2281 CCCAAAGCCA ACAAAGAAAT CTTAGACGAA GCATATGTGA TGGCTGGTGT GGGCTCCCCA
2341 TATGTCTCCC GCCTCCTGGG CATCTGCCTG ACATCCACGG TGCAGCTGGT GACACAGCTT
2401 ATGCCCTATG GCTGCCTCTT AGACCATGTC CGAGAAAACC GCGGACGCCT GGGCTCCCAG
2461 GACCTGCTGA ACTGGTGTAT GCAGATTGCC AAGGGGATGA GCTACCTGGA GGATGTGCGG
2522 CTCGTACACA GGGACTTGGC TGCTCGGAAC GTGCTGGTCA AGAGTCCCAA CCATGTCAAA
2581 ATTACAGACT TTGGGCTGGC TCGGCTGCTG GACATTGACG AGACAGAGTA CCATGCAGAT
2641 GGGGGCAAGG TGCCCATCAA GTGGATGGCG CTGGAGTCCA TTCTCCGACG GCGGTTACCG
2701 CACCAGAGTG ATGTGTGGAG TTATGGTGTG ACTGTGTGGG AGCTGATGAC TTTTGGGGCC
2761 AAACCTTACG ATGGGATCCC AGCCCGGGAG ATCCCTGACC TGCTGGAAAA GGGGGAGCGG
2821 CTGCCCCAGC CCCCCATCTG CACCATTGAT GTCTACATGA TCATGGTCAA ATGTTGGATG
2881 ATTGACTCTG AATGTCGGCC GAGATTCCGG GAGTTGGTGT CGGAATTCTC CCGCATGGCC
2941 AGGGACCCCC AGCGCTTTGT GGTCATCCAG AATGAGGACT TGGGGCCAGC CAGTCCCTTG
3001 GACAGCACCT TCTACCGCTC ACTGCTGGAG GACGATGACA TGGGGGACCT GGTGGATGCT
3061 GAGGAGTATC TGGTACCCCA GCAGGGCTTC TTCTGTCCAG ACCCTGCCCC GGGCACTGGG
3121 GGCATGGTCC ACCACAGGCA CCGCAGCTCA TCTACCAGGA GTGGCGGTGG GGACCTGACG
3181 CTAGGGCTGG AGCCCTCTGA AGAGGAGGCC CCCAGGTCTC CACRGGCACC CTCCGAAGGG
3241 ACTGGCTCTG ATGTATTTGA TGGTGACCTA GGAATGGGGG CAGCCAAGGG GCTGCAAAGC
3301 CTCCCCGCAC ATGACCCCAG CCCTCTACAG CGGTACAGTG AGGACCCAC GGTACCCCTG
3361 CTTTCTGAGA CTGACGGCTA CGTTGCCCCC CTGACCTGCA GYCCCCAGCC CGAATATGTG
3421 AACCAGCCAG ATGTTCGGCC ACAGCCCCCT TCGCCCCAAG AGGGCCCTCT GTCTCCTGCC
3481 CGACCTACTG GTGCCACTCT GGAAAGGCCC AAGACTCTCT CCCCAGGGAA GAATGGGGTT
3541 GTCAAAGACG TTTTGCCTT TGGGGGTGCT GTGGAGAACC CCGAGTACTT GGCACCCCGG
3601 GGAGGAGCTG CCCCTCAGCC CCACCTTCCT CCTGCCTTCA GCCCAGCCTT CGACAACCTC
3661 TATTACTGGG ACCAGGACCC ATCAGAGCGG GGGGCTCCAC CTAGCACCTT CAAAGGGACA
3721 CCTACGGCAG AGAACCAGAG GTACCTGGGT CTGGACGTGC CAGTGTGA (SEQ ID NO:40)

FIG.5B

8/9

Predicted Amino Acid Sequence of Second Rhesus Her2/Neu Protein

```

1  MELAAWYRWG LLLALLPPGA AGTQVCTGTD MKLRLPASPE THLDMLRHLY QGCQVVQGNL
61  ELTYLPTNAS LSFLQDIQEV QGYVLIHNPQ VRQVPLQRLR IVRGQTQLFED NYALAVLDNG
121 DPLNNTTPVT GASPGLREL QLRSLTEILK GGVLIQRNPQ LCYQDTILWK DIFHKNNQLA
181 LTLIDTNRSR ACHPCSPVCK GSRCWGESSE DCQSLTRTV C AGGCARCKGP LPTDCCHEQC
241 AAGCTGPKHS DCLACLFHNH SGICELHCPA LVTYNTDTFE SMPNPEGRYT FGASCVTACP
301 YNYLSTDVGS CTLVCPLHNQ EVTAEDGTQR CEKCSKPCAR VCYGLGMEHL REVRAVTSAN
361 IQEFAGCKKI FGSLAFLPES FDGDPASNTA PLQPEQLRVF ETLEEITGYL YISAWPDSLP
421 DLSVLQNLQV IRGRILHNGA YSLTLQGLGI SWLGLRSLRE LGSGLALIH NTRLCFVHTV
481 PWDQLFRNPH QALLHTANRP EDECVGEGLA' CHQLCAXGHC WGPGPQTQCVN CSQFLRGQEC
541 VEECRVLQGL PREYVNARHC LPCHPECQPQ NGSVTCFGPE ADQCVACAHY KDPPFCVARC
601 PSGVKPDLSY MPIWKFPDEE GTCQPCPINC THSCVDLDDK GCPAEQXASP LTSIISAVVG
661 ILLVVVLGVV FGILIKRRQQ KIRKYTMRR LQETELVEPL TPGAMPNQA QMRILKETEL
721 RKVKVLGSGA FGTVYKGIWI PDGENVKIPV AIKVLRENTS PKANKEILDE AYVMAGVGSP
781 YVSRLLGICL TSTVQLVTQL MPYGCLLDHV RENRGRLGSQ DLLNWCMIQIA KGMSYLEDVR
841 LVHRDLAARN VLVKSPNHVK ITDFGLARLL DIDETEHYHAD GGKVPIKWMA LESILRRRFT
901 HQSDVWSYGV TVWELMTFGA KPYDGIPARE IPDLLEKGER LPQPPICTID VYMIMVKCWM
961 IDSECRPRFR ELVSEFSRMA RDPQRFVVIQ NEDLGPASPL DSTFYRSLLE DDDMGDLVDA
1021 EEYLVPQQGF FCPDPAPGTG GMVHHRHRSS STRSGGGDLT LGLEPSEEEA PRSPXAPSEG
1081 TGSDVFDGDL GMGAAGLQS LPAHDPSPLQ RYSEDPTVPL PSETDGYVAP LTCSPQPEYV
1141 NQPDVRPQPP SPQEGPLSPA RPTGATLERP KTLSPGKNGV VKDVFAFGGA VENPEYLAPR
1201 GGAAPQPHLP PAFSPAFDNL YYWDQDP SER GAPPSTFKGT PTAENPEYLG LDVPV*
(SEQ ID NO:41)

```

FIG.6

9/9

MUTATIONS IN RHESUS HER2/neu NUCLEOTIDE SEQUENCE

POSITION	RhHER2#1		POSITION	RhHER2#2	
365	2 CLONES	C T G L	365	2 CLONES	C C G P
795	3 CLONES	G A G E	795	1 CLONE	G A G E
	2 CLONES	G A A E		2 CLONES	G A A E
1119	2 CLONES	A G C S	1119	3 CLONES	A G T S
				2 CLONES	A G C S
1550	3 CLONES	C G A R	1550	2 CLONES	C A A Q
				3 CLONES	C G A R
1873	6 CLONES	T C T S	1873	11 CLONES	C C T P
1940	2 CLONES	A G A R	1940	3 CLONES	A A A K
				3 CLONES	A G A R
3224	4 CLONES	C G G R	3224	5 CLONES	C G G R
				3 CLONES	C A G Q
3402	2 CLONES	A G T S	3402	2 CLONES	A G C S
				6 CLONES	A G T S

FIG.7

SEQUENCE LISTING

<110> Merck & Co., Inc.
 Monaci, Paolo
 Nuzzo, Maurizio
 La Monica, Nicola
 Ciliberto, Gennaro
 Lahm, Armin

<120> RHESUS HER2/NEU, NUCLEOTIDES ENCODING
 SAME AND USES THEREOF

<130> ITR0043-PCT

<150> 60/437,846

<151> 2003-01-03

<160> 43

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 3768

<212> DNA

<213> Rhesus Monkey

<220>

<221> misc_feature

<222> (1)...(3768)

<223> R = A or G

<400> 1

```

atggagctgg cggcctggta cegctggggg ctctctctcg cctctttgcc ccccgagct 60
gcgggcaccc aagtgtgcac cggcacagac atgaagctgc ggctccctgc cagtcccag 120
acccacctgg acatgtctcg ccacctctac cagggtctgc aggtggtgca gggtaacctg 180
gaactcacct acctgccac caatgccagc ctctccttcc tgcaggatat ccaggaggtg 240
cagggtacg tgtcatcgc tcacaaccaa gtgaggcagg tccactgca gaggtgcgg 300
attgtgcgag gcacccagct ctttgaggac aactatgccc tggccgtgct agacaatgga 360
gacctgtga acaataccac ccctgtcaca ggggcctccc caggaggcct gcgggagctg 420
cagcttcgaa gcctcacaga gatcttgaag ggaggggtct tgatccagcg gaacccccag 480
ctctgtctacc aggacacgat tttgtggaag gacatcttcc ataagaacaa ccagctggct 540
ctcacactga tcgacaccaa ccgtctcgg gctgccacc cctgttctcc agtgtgtaag 600
ggctcccgct gctggggaga gaggttctgag gattgtcaga gctgacgcg cactgtctgt 660
gcgggtggct gtgcccgtg caaggggcca ctgccactg actgctgcca tgagcagtgt 720
gctgccggct gcacgggccc caagcactct gactgcctgg cctgcctcca cttcaaccac 780
agcggcatct gtgarctgca ctgcccagcc ctggctacct acaacacaga cacctttgag 840
tccatgccca acccgaggg cgggtataca ttccggcgcca gctgtgtgac tgcctgtccc 900
tacaactacc tttctacgga cgtgggatcc tgcacctcg tctgccccct gcacaaccaa 960
gaggtgacag cggaggacgg aacacagcga tgtgagaagt gcagcaagcc ctgtgcccga 1020
gtgtgtctatg gtctgggcat ggagcacttg cgagaggtga gggcggtcac cagtgccaat 1080
atccaggagt ttgctggctg caagaagatc tttgggagct tggcatttct gccagagagc 1140
tttgatggcg acccagcctc caacaccgcc ccgcttcagc cggagcagct ccgagtgttt 1200
gagactctgg aagagatcac aggttaccta tacatctcag catggccaga cagcctgcct 1260
gaccttagcg tcctccagaa cctgcaagta atccggggac gaattctgca caatggcgcc 1320
tactactga ccctgcaagg gctgggcata agctggctgg ggctgcgctc gctgagggaa 1380
ctgggcagtg gactggccct catccaccat aacaccgcc tctgctttgt gcacacgggtg 1440
ccctgggacc agctcttccg gaacccgcac caagccctgc tccacactgc caaccggcca 1500
gaggacgagt gtgtgggcga gggcctggcc tgccaccagc tgtgcgcccg agggcactgc 1560
tggggctcag ggcccaccca gtgtgtcaac tgcagccagt tccttcgggg ccaggagtgc 1620
gtggaggaat gccgagtact gcaggggctc cccaggagat atgtgaatgc cagacactgt 1680
ttgccgtgcc accctgagtg tcagccccag aatggctcag tgacatgttt tggaccggag 1740
gctgaccagt gtgtggcctg tgcccactat aaggaccctc ccttctgcgt ggcccgcgtg 1800
cccagcggtg tgaacctga cctctctac atgcccactt ggaagtttcc agatgaggag 1860

```

```

ggcacgtgcc agtcttgccc catcaactgc acccactcct gtgtggacct ggatgacaag 1920
ggctgccccg ccgagcagag agccagccct ctgacgtcca tcatctctgc tgtggtgggc 1980
attctgctgg tcgtggtctt gggggtggtc tttggaatcc tcatcaagcg acggcagcag 2040
aagatccgga agtacacgat gcggaggctg ctgcaggaaa cggagctggt ggagccactg 2100
acaccgagtg gagcgatgcc caaccaggcg cagatgcgga tcctgaaaga gacggagctg 2160
aggaaggtga aggtgcttgg atctggagct tttggcacag tctacaaggg catctggatc 2220
cctgatgggg agaatgtgaa aattccagtg gccatcaaag tggtgagggg aaacacatcc 2280
cccaaagcca acaaagaaat cttagacgaa gcatatgtga tggctggtgt gggctcccca 2340
tatgtctccc gcctcctggg catctgcctg acatccacgg tgcagctggt gacacagctt 2400
atgccttatg gctgcctctt agaccatgtc cgagaaaacc gcggacgcct gggctcccag 2460
gacctgctga actggtgtat gcagattgcc aaggggatga gctacctgga ggatgtgcgg 2520
ctcgtacaca gggacttggc tgctcggaac gtgctggtca agagtcccaa ccatgtcaaa 2580
attacagact ttgggctggc tcggctgctg gacattgacg agacagagta ccatgcagat 2640
gggggcaagg tgcccatcaa gtggatggcg ctgaggtcca ttctccgacg gcggttcacc 2700
caccagagtg atgtgtggag ttatggtgtg actgtgtggg agctgatgac ttttggggcc 2760
aaaccttacg atgggatccc agcccgggag atccctgacc tgctggaaaa gggggagcgg 2820
ctgccccagc ccccatctct caccattgat gtctacatga tcatggtcaa atgttggtg 2880
attgactctg aatgtcggcc gagattccgg gagttggtgt cggaaattctc ccgcatggcc 2940
agggaccccc agcgctttgt ggtcatccag aatgaggact tggggccagc cagtcccttg 3000
gacagcacct tctaccgctc actgctggag gacgatgaca tgggggacct ggtggatgct 3060
gaggagtatc tggtaaccca gcagggttc ttctgtccag accctgcccc gggcactggg 3120
ggcatggtcc accacaggca ccgagctca tctaccagga gtggcggtgg ggacctgacg 3180
ctagggctgg agccctctga agaggaggcc cccaggtctc caccgggcacc ctccgaaggg 3240
actggctctg atgtatttga tggtagacct ggaatggggg cagccaaggg gctgcaaagc 3300
ctccccgcac atgaccccag ccctctacag cggtacagtg aggacccac ggtacccttg 3360
cctcttgaga ctgacggcta cgtagccccc ctgacctgca gtccccagcc cgaatatgtg 3420
aaccagccag atgttcggcc acagccccct tcgccccaaag agggccctct gtctcctgcc 3480
cgacctactg gtgccactct ggaaaggccc aagactctct ccccaggga gaatggggtt 3540
gtcaaagacg tttttgcctt tgggggtgct gtggagaacc ccgagtactt ggcaccccg 3600
ggaggagctg cccctcagcc ccaccttct cctgccttca gccagcctt cgacaacctc 3660
tattactggg accaggaccc atcagagcgg ggggctccac ctagcacctt caaagggaca 3720
cctacggcag agaaccacga gtacctgggt ctggacgtgc cagtgtga 3768

```

<210> 2

<211> 1255

<212> PRT

<213> Rhesus Monkey

<400> 2

```

Met Glu Leu Ala Ala Trp Tyr Arg Trp Gly Leu Leu Leu Ala Leu Leu
1          5          10          15
Pro Pro Gly Ala Ala Gly Thr Gln Val Cys Thr Gly Thr Asp Met Lys
20          25          30
Leu Arg Leu Pro Ala Ser Pro Glu Thr His Leu Asp Met Leu Arg His
35          40          45
Leu Tyr Gln Gly Cys Gln Val Val Gln Gly Asn Leu Glu Leu Thr Tyr
50          55          60
Leu Pro Thr Asn Ala Ser Leu Ser Phe Leu Gln Asp Ile Gln Glu Val
65          70          75          80
Gln Gly Tyr Val Leu Ile Ala His Asn Gln Val Arg Gln Val Pro Leu
85          90          95
Gln Arg Leu Arg Ile Val Arg Gly Thr Gln Leu Phe Glu Asp Asn Tyr
100          105          110
Ala Leu Ala Val Leu Asp Asn Gly Asp Leu Leu Asn Asn Thr Thr Pro
115          120          125
Val Thr Gly Ala Ser Pro Gly Gly Leu Arg Glu Leu Gln Leu Arg Ser
130          135          140
Leu Thr Glu Ile Leu Lys Gly Gly Val Leu Ile Gln Arg Asn Pro Gln
145          150          155          160
Leu Cys Tyr Gln Asp Thr Ile Leu Trp Lys Asp Ile Phe His Lys Asn
165          170          175
Asn Gln Leu Ala Leu Thr Leu Ile Asp Thr Asn Arg Ser Arg Ala Cys
180          185          190
His Pro Cys Ser Pro Val Cys Lys Gly Ser Arg Cys Trp Gly Glu Ser

```

- 3 -

705					710					715					720
Arg	Lys	Val	Lys	Val	Leu	Gly	Ser	Gly	Ala	Phe	Gly	Thr	Val	Tyr	Lys
				725					730					735	
Gly	Ile	Trp	Ile	Pro	Asp	Gly	Glu	Asn	Val	Lys	Ile	Pro	Val	Ala	Ile
			740					745					750		
Lys	Val	Leu	Arg	Glu	Asn	Thr	Ser	Pro	Lys	Ala	Asn	Lys	Glu	Ile	Leu
		755					760					765			
Asp	Glu	Ala	Tyr	Val	Met	Ala	Gly	Val	Gly	Ser	Pro	Tyr	Val	Ser	Arg
	770					775					780				
Leu	Leu	Gly	Ile	Cys	Leu	Thr	Ser	Thr	Val	Gln	Leu	Val	Thr	Gln	Leu
785					790					795					800
Met	Pro	Tyr	Gly	Cys	Leu	Leu	Asp	His	Val	Arg	Glu	Asn	Arg	Gly	Arg
				805					810					815	
Leu	Gly	Ser	Gln	Asp	Leu	Leu	Asn	Trp	Cys	Met	Gln	Ile	Ala	Lys	Gly
			820					825					830		
Met	Ser	Tyr	Leu	Glu	Asp	Val	Arg	Leu	Val	His	Arg	Asp	Leu	Ala	Ala
		835				840					845				
Arg	Asn	Val	Leu	Val	Lys	Ser	Pro	Asn	His	Val	Lys	Ile	Thr	Asp	Phe
	850					855					860				
Gly	Leu	Ala	Arg	Leu	Leu	Asp	Ile	Asp	Glu	Thr	Glu	Tyr	His	Ala	Asp
865					870					875					880
Gly	Gly	Lys	Val	Pro	Ile	Lys	Trp	Met	Ala	Leu	Glu	Ser	Ile	Leu	Arg
				885					890					895	
Arg	Arg	Phe	Thr	His	Gln	Ser	Asp	Val	Trp	Ser	Tyr	Gly	Val	Thr	Val
		900						905					910		
Trp	Glu	Leu	Met	Thr	Phe	Gly	Ala	Lys	Pro	Tyr	Asp	Gly	Ile	Pro	Ala
		915				920						925			
Arg	Glu	Ile	Pro	Asp	Leu	Leu	Glu	Lys	Gly	Glu	Arg	Leu	Pro	Gln	Pro
	930				935					940					
Pro	Ile	Cys	Thr	Ile	Asp	Val	Tyr	Met	Ile	Met	Val	Lys	Cys	Trp	Met
945					950					955					960
Ile	Asp	Ser	Glu	Cys	Arg	Pro	Arg	Phe	Arg	Glu	Leu	Val	Ser	Glu	Phe
				965					970					975	
Ser	Arg	Met	Ala	Arg	Asp	Pro	Gln	Arg	Phe	Val	Val	Ile	Gln	Asn	Glu
		980						985					990		
Asp	Leu	Gly	Pro	Ala	Ser	Pro	Leu	Asp	Ser	Thr	Phe	Tyr	Arg	Ser	Leu
	995					1000						1005			
Leu	Glu	Asp	Asp	Asp	Met	Gly	Asp	Leu	Val	Asp	Ala	Glu	Glu	Tyr	Leu
	1010					1015					1020				
Val	Pro	Gln	Gln	Gly	Phe	Phe	Cys	Pro	Asp	Pro	Ala	Pro	Gly	Thr	Gly
1025					1030					1035					1040
Gly	Met	Val	His	His	Arg	His	Arg	Ser	Ser	Ser	Thr	Arg	Ser	Gly	Gly
				1045					1050					1055	
Gly	Asp	Leu	Thr	Leu	Gly	Leu	Glu	Pro	Ser	Glu	Glu	Glu	Ala	Pro	Arg
			1060					1065					1070		
Ser	Pro	Arg	Ala	Pro	Ser	Glu	Gly	Thr	Gly	Ser	Asp	Val	Phe	Asp	Gly
		1075					1080					1085			
Asp	Leu	Gly	Met	Gly	Ala	Ala	Lys	Gly	Leu	Gln	Ser	Leu	Pro	Ala	His
	1090					1095					1100				
Asp	Pro	Ser	Pro	Leu	Gln	Arg	Tyr	Ser	Glu	Asp	Pro	Thr	Val	Pro	Leu
1105					1110					1115					1120
Pro	Ser	Glu	Thr	Asp	Gly	Tyr	Val	Ala	Pro	Leu	Thr	Cys	Ser	Pro	Gln
				1125					1130					1135	
Pro	Glu	Tyr	Val	Asn	Gln	Pro	Asp	Val	Arg	Pro	Gln	Pro	Pro	Ser	Pro
			1140					1145					1150		
Gln	Glu	Gly	Pro	Leu	Ser	Pro	Ala	Arg	Pro	Thr	Gly	Ala	Thr	Leu	Glu
		1155					1160					1165			
Arg	Pro	Lys	Thr	Leu	Ser	Pro	Gly	Lys	Asn	Gly	Val	Val	Lys	Asp	Val
	1170						1175					1180			
Phe	Ala	Phe	Gly	Gly	Ala	Val	Glu	Asn	Pro	Glu	Tyr	Leu	Ala	Pro	Arg
1185					1190				1195						1200
Gly	Gly	Ala	Ala	Pro	Gln	Pro	His	Leu	Pro	Pro	Ala	Phe	Ser	Pro	Ala
				1205					1210					1215	
Phe	Asp	Asn	Leu	Tyr	Tyr	Trp	Asp	Gln	Asp	Pro	Ser	Glu	Arg	Gly	Ala

	1220		1225		1230
Pro	Pro	Ser	Thr	Phe	Lys
			Gly	Thr	Pro
	1235			1240	
Leu	Gly	Leu	Asp	Val	Pro
	1250			1255	

<210> 3
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 3
 agccatgggg ccggagccgc a 21

<210> 4
 <211> 26
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 4
 agggctgggc agtgcagctc acagat 26

<210> 5
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 5
 ctgcgggagc tgcagcttcg aag 23

<210> 6
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 6
 ccaaagatct tcttgcagcc 20

<210> 7
 <211> 26
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 7
 atctgtgagc tgcactgccc agccct 26

<210> 8
 <211> 19

<212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 8
 gagcgcagcc ccagccagc 19

<210> 9
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 9
 ggctgcaaga agatctttgg 20

<210> 10
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 10
 tgggtgcagt tgatggggca 20

<210> 11
 <211> 44
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 11
 ccagtttaaa catttaaattg ccgccaccat ggagctggcg gcct 44

<210> 12
 <211> 26
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 12
 tgctggggtc cagggccac ccagtg 26

<210> 13
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 13
 tcagggatct cccgggctgg gat 23

<210> 14
 <211> 24
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 14
 gtggaggaat gccgagtact gcag 24

<210> 15
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 15
 tgtgttttcc ctcaacacgg cgatggccac tggaatttt 39

<210> 16
 <211> 39
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 16
 aaaattccag tggccatcgc cgtgttgagg gaaaacaca 39

<210> 17
 <211> 23
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 17
 ctgggcatct gcctgacatc cac 23

<210> 18
 <211> 22
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 18
 ggtttcaggg acagtctctg aa 22

<210> 19
 <211> 32
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> PCR Primer

<400> 19

gccgtcgact ttacatggca cgtccagacc ca 32
<210> 20
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 20
cttcatgtct gtgccggt 18

<210> 21
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 21
ggccggagcc gcagtgagca cc 22

<210> 22
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 22
cttcgaagct gcagctccccg cag 23

<210> 23
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 23
atggagctgg cggccttggtg ccgct 25

<210> 24
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 24
accggcacag acatgaag 18

<210> 25
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 25
cactgggtgg gccctggacc ccagca 26

<210> 26
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 26
gatccaagca ccttcacctt cct 23

<210> 27
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 27
gctggctggg gctgcgctc 19

<210> 28
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 28
gggatccaga tgcccttgta gac 23

<210> 29
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 29
tgcccatca actgcaccca 20

<210> 30
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 30
gtggatgtca ggcatatgcc cag 23

<210> 31
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 31
aggaaggtga aggtgcttgg atc 23

<210> 32
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 32
taaggtttgg ccccaaaagt catcag 26

<210> 33
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 33
gtctacaagg gcatctggat ccc 23

<210> 34
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 34
ggctgggggc tgcaggtcag ggg 23

<210> 35
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 35
ctgatgactt ttggggccaa acctta 26

<210> 36
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> PCR Primer

<400> 36
ttctgaggac ttggccttct gg 22

<210> 37
<211> 23
<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 37

atcccagccc gggagatccc tga

23

<210> 38

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 38

tggcagggttc ccctgga

17

<210> 39

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> PCR Primer

<400> 39

cccctgacct gcagccccca gcc

23

<210> 40

<211> 3768

<212> DNA

<213> Rhesus Monkey

<220>

<221> misc_feature

<222> (1)...(3768)

<223> R = A or G

<221> misc_feature

<222> (1)...(3768)

<223> Y = C or T

<400> 40

```

atggagctgg cgccctggta ccgctggggg ctctctctcg cctctttgcc ccccgagct 60
gcgggcaccc aagtgtgcac cggcacagac atgaagctgc ggctccctgc cagtcccag 120
acccacctgg acatgctccg ccacctctac cagggctgcc aggtggtgca gggtaacctg 180
gaactcacct acctgcccac caatgccagc ctctccttcc tgcaggatat ccaggaggtg 240
cagggctacg tgctcatcgc tcacaaccaa gtgaggcagg tccactgca gaggctgcgg 300
attgtgcgag gcacccagct ctttgaggac aactatgcc tggccgtgct agacaatgga 360
gaccogctga acaataccac ccctgtcaca ggggcctccc caggaggcct gcgggagctg 420
cagcttcgaa gcctcacaga gatcttgaag ggaggggtct tgatccagcg gaacccccag 480
ctctgctacc aggacacgat tttgtggaag gacatcttcc ataagaacaa ccagctggct 540
ctcacactga tcgacaccaa ccgctctcgg gcctgccacc cctgttctcc agtgtgtgtaag 600
ggctcccgtg gctggggaga gagttctgag gattgtcaga gcctgacgcg cactgtctgt 660
gccggtggct gtgcccgtcg caagggggcca ctgcccactg actgctgcca tgagcagtg 720
gctgcgggct gcacggggccc caagcactct gactgcctgg cctgcctcca cttcaaccac 780
agcggcatct gtgarctgca ctgcccagcc ctgggtcaoct acaacacaga cacctttgag 840
tccatgcccc accccgaggg ccggtataca ttggcgcca gctgtgtgac tgctgttccc 900
tacaactacc tttctacgga cgtgggatcc tgcacctcg tctgccccct gcacaaccaa 960
gaggtgacag cggaggacgg aacacagcga tgtgagaagt gcagcaagcc ctgtgcccga 1020
gtgtgctatg gtctgggcat ggagcacttg cgagaggtga gggcggtcac cagtggcaat 1080
atccaggagt ttgctggctg caagaagatc tttgggagyt tggcatttct gccagagagc 1140

```

```

ttt gatggcg acccagcctc caacaccgcc cgcgttcagc cggagcagct ccgagtgttt 1200
gagactctgg aagagatcac aggttaccta tacatctcag catggccaga cagcctgctt 1260
gaccttagcg tcttccagaa cctgcaagta atccggggac gaattctgca caatggcgcc 1320
tactactga ccctgcaagg gctgggcatc agctggctgg ggctgcgctc gctgagggaa 1380
ctgggcagtg gactggccct catccaccat aacaccgcc tctgctttgt gcacacggtg 1440
ccctgggacc agctcttccg gaaccgcgac caagccctgc tccacactgc caaccggcca 1500
gaggacgagt gtgtgggcga gggcctggcc tggcaccagc tgtgcgccc r agggcactgc 1560
tggggtccag ggccaccca gtgtgtcaac tgcagccagt tccttcgggg ccaggagtgc 1620
gtggaggaat gccgagtact gcaggggctc cccagggagt atgtgaatgc cagacactgt 1680
ttgccgtgcc accctgagtg tcagcccag aatggctcag tgacatgttt tggaccggag 1740
gctgaccagt gtgtggcctg tgcccactat aaggaccctc ccttctgcgt ggcccgtgc 1800
cccagcgggtg tgaacactga cctctcctac atgcccactt ggaagtttc agatgaggag 1860
ggcagctgcc agccttgccc catcaactgc acccactcct gtgtggacct ggatgacaag 1920
ggctgccccg ccgagcagar agccagccct ctgacgtcca tcatctctgc tgtggtgggc 1980
attctgctgg tctgtgtctt gggggtggtc tttggaatcc tcatcaagcg acggcagcag 2040
aagatccgga agtacacgat gcggaggctg ctgcaggaaa cggagctggt ggagccactg 2100
acaccgagtg gagcgatgcc caaccaggcg cagatgcgga tcctgaaaga gacggagctg 2160
aggaaggatga aggtgcttgg atctggagct tttggcacag tctacaaggg catctggatc 2220
cctgatgggg agaatgtgaa aattccagtg gccatcaaag tgttgaggga aaacacatcc 2280
cccaaagcca acaaagaaat cttagacgaa gcatatgtga tggctgggtg gggctcccc 2340
tatgtctccc gcctcctggg catctgcctg acatccacgg tgacgtggt gacacagctt 2400
atgccctatg gctgcctctt agaccatgtc cgagaaaacc gcggacgcct gggctcccag 2460
gacctgctga actggtgtat gcagattgcc aaggggatga gctacctgga ggatgtgcgg 2520
ctcgtacaca gggacttggc tgctcggaac gtgctgggtc agagtcccaa ccatgtcaaa 2580
attacagact ttgggctggc tcggctgctg gacattgacg agacagagta ccatgcagat 2640
gggggcaagg tgcccacaa gtggatggcg ctggagtcca ttctccgacg gcggttcacc 2700
caccagagtg atgtgtggag ttatggtgtg actgtgtggg agctgatgac ttttggggcc 2760
aaaccttacg atgggatccc agcccgggag atccctgacc tgctggaaaa gggggagcgg 2820
ctgcccagc ccccatctg caccattgat gtctacatga tcatggtcaa atgttgatg 2880
attgactctg aatgtcggcc gagattccgg gagttggtgt cggaaattct cgcgatggcc 2940
agggaccccc agcgcttgt ggtcatccag aatgaggact tgggcccagc cagtcccttg 3000
gacagcacct tctaccgctc actgctggag gacgatgaca tgggggacct ggtggatgct 3060
gaggagtatc tggtaaccca gcagggttc ttctgtccag accctgcccc gggcactggg 3120
ggcatggtcc accacaggca ccgcagctca tctaccagga gtggcgggtg ggacctgacg 3180
ctagggctgg agccctctga agaggaggcc cccaggtctc cacrggcacc ctccgaaggg 3240
actggtctctg atgtatttga tggtgacct ggaatggggg cagccaaggg gctgcaaagc 3300
ctccccgcac atgaccccag ccctctacag cggtagactg aggacccac ggtacccctg 3360
ccttctgaga ctgacggcta cgttgcccc ctgacctgca gyccccagcc cgaatatgtg 3420
aaccagccag atgttcggcc acagccccct tcgccccaa agggccctct gtctcctgcc 3480
cgacctactg gtgccactct ggaaaggccc aagactctct ccccagggaa gaatgggggt 3540
gtcaaagacg tttttgcctt tgggggtgct gtggagaacc ccgagtactt ggcaccccg 3600
ggaggagctg cccctcagcc ccaccttct cctgccttca gccagcctt cgacaacctc 3660
tattactggg accaggaccc atcagagcgg ggggctccac ctagcacctt caaagggaca 3720
cctacggcag agaaccacga gtacctgggt ctggacgtgc cagtgtga 3768

```

<210> 41
 <211> 1255
 <212> PRT
 <213> Rhesus Monkey

<220>
 <221> VARIANT
 <222> 517
 <223> Xaa = Q or R

<221> VARIANT
 <222> 647
 <223> Xaa = K or R

<221> VARIANT
 <222> 1075
 <223> Xaa = Q or R

<400> 41

Met	Glu	Leu	Ala	Ala	Trp	Tyr	Arg	Trp	Gly	Leu	Leu	Leu	Ala	Leu	Leu
1				5					10					15	
Pro	Pro	Gly	Ala	Ala	Gly	Thr	Gln	Val	Cys	Thr	Gly	Thr	Asp	Met	Lys
			20					25					30		
Leu	Arg	Leu	Pro	Ala	Ser	Pro	Glu	Thr	His	Leu	Asp	Met	Leu	Arg	His
		35					40					45			
Leu	Tyr	Gln	Gly	Cys	Gln	Val	Val	Gln	Gly	Asn	Leu	Glu	Leu	Thr	Tyr
	50					55					60				
Leu	Pro	Thr	Asn	Ala	Ser	Leu	Ser	Phe	Leu	Gln	Asp	Ile	Gln	Glu	Val
65					70					75				80	
Gln	Gly	Tyr	Val	Leu	Ile	Ala	His	Asn	Gln	Val	Arg	Gln	Val	Pro	Leu
				85					90					95	
Gln	Arg	Leu	Arg	Ile	Val	Arg	Gly	Thr	Gln	Leu	Phe	Glu	Asp	Asn	Tyr
			100					105					110		
Ala	Leu	Ala	Val	Leu	Asp	Asn	Gly	Asp	Pro	Leu	Asn	Asn	Thr	Thr	Pro
		115					120					125			
Val	Thr	Gly	Ala	Ser	Pro	Gly	Gly	Leu	Arg	Glu	Leu	Gln	Leu	Arg	Ser
	130					135					140				
Leu	Thr	Glu	Ile	Leu	Lys	Gly	Gly	Val	Leu	Ile	Gln	Arg	Asn	Pro	Gln
145					150					155					160
Leu	Cys	Tyr	Gln	Asp	Thr	Ile	Leu	Trp	Lys	Asp	Ile	Phe	His	Lys	Asn
				165					170					175	
Asn	Gln	Leu	Ala	Leu	Thr	Leu	Ile	Asp	Thr	Asn	Arg	Ser	Arg	Ala	Cys
			180					185					190		
His	Pro	Cys	Ser	Pro	Val	Cys	Lys	Gly	Ser	Arg	Cys	Trp	Gly	Glu	Ser
		195					200						205		
Ser	Glu	Asp	Cys	Gln	Ser	Leu	Thr	Arg	Thr	Val	Cys	Ala	Gly	Gly	Cys
	210					215					220				
Ala	Arg	Cys	Lys	Gly	Pro	Leu	Pro	Thr	Asp	Cys	Cys	His	Glu	Gln	Cys
225					230					235					240
Ala	Ala	Gly	Cys	Thr	Gly	Pro	Lys	His	Ser	Asp	Cys	Leu	Ala	Cys	Leu
			245						250					255	
His	Phe	Asn	His	Ser	Gly	Ile	Cys	Glu	Leu	His	Cys	Pro	Ala	Leu	Val
		260						265					270		
Thr	Tyr	Asn	Thr	Asp	Thr	Phe	Glu	Ser	Met	Pro	Asn	Pro	Glu	Gly	Arg
		275					280						285		
Tyr	Thr	Phe	Gly	Ala	Ser	Cys	Val	Thr	Ala	Cys	Pro	Tyr	Asn	Tyr	Leu
	290					295					300				
Ser	Thr	Asp	Val	Gly	Ser	Cys	Thr	Leu	Val	Cys	Pro	Leu	His	Asn	Gln
305					310					315					320
Glu	Val	Thr	Ala	Glu	Asp	Gly	Thr	Gln	Arg	Cys	Glu	Lys	Cys	Ser	Lys
			325						330					335	
Pro	Cys	Ala	Arg	Val	Cys	Tyr	Gly	Leu	Gly	Met	Glu	His	Leu	Arg	Glu
		340						345					350		
Val	Arg	Ala	Val	Thr	Ser	Ala	Asn	Ile	Gln	Glu	Phe	Ala	Gly	Cys	Lys
		355					360					365			
Lys	Ile	Phe	Gly	Ser	Leu	Ala	Phe	Leu	Pro	Glu	Ser	Phe	Asp	Gly	Asp
	370					375					380				
Pro	Ala	Ser	Asn	Thr	Ala	Pro	Leu	Gln	Pro	Glu	Gln	Leu	Arg	Val	Phe
385					390					395					400
Glu	Thr	Leu	Glu	Glu	Ile	Thr	Gly	Tyr	Leu	Tyr	Ile	Ser	Ala	Trp	Pro
			405						410					415	
Asp	Ser	Leu	Pro	Asp	Leu	Ser	Val	Leu	Gln	Asn	Leu	Gln	Val	Ile	Arg
			420					425					430		
Gly	Arg	Ile	Leu	His	Asn	Gly	Ala	Tyr	Ser	Leu	Thr	Leu	Gln	Gly	Leu
		435					440					445			
Gly	Ile	Ser	Trp	Leu	Gly	Leu	Arg	Ser	Leu	Arg	Glu	Leu	Gly	Ser	Gly
	450					455					460				
Leu	Ala	Leu	Ile	His	His	Asn	Thr	Arg	Leu	Cys	Phe	Val	His	Thr	Val
465					470					475					480
Pro	Trp	Asp	Gln	Leu	Phe	Arg	Asn	Pro	His	Gln	Ala	Leu	Leu	His	Thr
			485						490					495	
Ala	Asn	Arg	Pro	Glu	Asp	Glu	Cys	Val	Gly	Glu	Gly	Leu	Ala	Cys	His
			500					505					510		

Gln	Leu	Cys	Ala	Xaa	Gly	His	Cys	Trp	Gly	Pro	Gly	Pro	Thr	Gln	Cys
		515					520					525			
Val	Asn	Cys	Ser	Gln	Phe	Leu	Arg	Gly	Gln	Glu	Cys	Val	Glu	Glu	Cys
	530					535					540				
Arg	Val	Leu	Gln	Gly	Leu	Pro	Arg	Glu	Tyr	Val	Asn	Ala	Arg	His	Cys
545					550					555					560
Leu	Pro	Cys	His	Pro	Glu	Cys	Gln	Pro	Gln	Asn	Gly	Ser	Val	Thr	Cys
			565						570					575	
Phe	Gly	Pro	Glu	Ala	Asp	Gln	Cys	Val	Ala	Cys	Ala	His	Tyr	Lys	Asp
		580						585					590		
Pro	Pro	Phe	Cys	Val	Ala	Arg	Cys	Pro	Ser	Gly	Val	Lys	Pro	Asp	Leu
	595						600					605			
Ser	Tyr	Met	Pro	Ile	Trp	Lys	Phe	Pro	Asp	Glu	Glu	Gly	Thr	Cys	Gln
	610					615					620				
Pro	Cys	Pro	Ile	Asn	Cys	Thr	His	Ser	Cys	Val	Asp	Leu	Asp	Asp	Lys
625				630						635					640
Gly	Cys	Pro	Ala	Glu	Gln	Xaa	Ala	Ser	Pro	Leu	Thr	Ser	Ile	Ile	Ser
			645						650					655	
Ala	Val	Val	Gly	Ile	Leu	Leu	Val	Val	Val	Leu	Gly	Val	Val	Phe	Gly
		660						665					670		
Ile	Leu	Ile	Lys	Arg	Arg	Gln	Gln	Lys	Ile	Arg	Lys	Tyr	Thr	Met	Arg
	675					680						685			
Arg	Leu	Gln	Glu	Thr	Glu	Leu	Val	Glu	Pro	Leu	Thr	Pro	Ser	Gly	
	690				695					700					
Ala	Met	Pro	Asn	Gln	Ala	Gln	Met	Arg	Ile	Leu	Lys	Glu	Thr	Glu	Leu
705				710					715						720
Arg	Lys	Val	Lys	Val	Leu	Gly	Ser	Gly	Ala	Phe	Gly	Thr	Val	Tyr	Lys
			725						730					735	
Gly	Ile	Trp	Ile	Pro	Asp	Gly	Glu	Asn	Val	Lys	Ile	Pro	Val	Ala	Ile
	740							745					750		
Lys	Val	Leu	Arg	Glu	Asn	Thr	Ser	Pro	Lys	Ala	Asn	Lys	Glu	Ile	Leu
	755						760					765			
Asp	Glu	Ala	Tyr	Val	Met	Ala	Gly	Val	Gly	Ser	Pro	Tyr	Val	Ser	Arg
	770					775					780				
Leu	Leu	Gly	Ile	Cys	Leu	Thr	Ser	Thr	Val	Gln	Leu	Val	Thr	Gln	Leu
785					790					795					800
Met	Pro	Tyr	Gly	Cys	Leu	Leu	Asp	His	Val	Arg	Glu	Asn	Arg	Gly	Arg
			805						810					815	
Leu	Gly	Ser	Gln	Asp	Leu	Leu	Asn	Trp	Cys	Met	Gln	Ile	Ala	Lys	Gly
			820					825					830		
Met	Ser	Tyr	Leu	Glu	Asp	Val	Arg	Leu	Val	His	Arg	Asp	Leu	Ala	Ala
	835						840					845			
Arg	Asn	Val	Leu	Val	Lys	Ser	Pro	Asn	His	Val	Lys	Ile	Thr	Asp	Phe
	850					855					860				
Gly	Leu	Ala	Arg	Leu	Leu	Asp	Ile	Asp	Glu	Thr	Glu	Tyr	His	Ala	Asp
865					870					875					880
Gly	Gly	Lys	Val	Pro	Ile	Lys	Trp	Met	Ala	Leu	Glu	Ser	Ile	Leu	Arg
			885						890					895	
Arg	Arg	Phe	Thr	His	Gln	Ser	Asp	Val	Trp	Ser	Tyr	Gly	Val	Thr	Val
		900						905					910		
Trp	Glu	Leu	Met	Thr	Phe	Gly	Ala	Lys	Pro	Tyr	Asp	Gly	Ile	Pro	Ala
	915						920						925		
Arg	Glu	Ile	Pro	Asp	Leu	Leu	Glu	Lys	Gly	Glu	Arg	Leu	Pro	Gln	Pro
	930					935					940				
Pro	Ile	Cys	Thr	Ile	Asp	Val	Tyr	Met	Ile	Met	Val	Lys	Cys	Trp	Met
945					950					955					960
Ile	Asp	Ser	Glu	Cys	Arg	Pro	Arg	Phe	Arg	Glu	Leu	Val	Ser	Glu	Phe
			965						970					975	
Ser	Arg	Met	Ala	Arg	Asp	Pro	Gln	Arg	Phe	Val	Val	Ile	Gln	Asn	Glu
		980						985					990		
Asp	Leu	Gly	Pro	Ala	Ser	Pro	Leu	Asp	Ser	Thr	Phe	Tyr	Arg	Ser	Leu
	995						1000					1005			
Leu	Glu	Asp	Asp	Asp	Met	Gly	Asp	Leu	Val	Asp	Ala	Glu	Glu	Tyr	Leu
1010						1015					1020				

Val Pro Gln Gln Gly Phe Phe Cys Pro Asp Pro Ala Pro Gly Thr Gly
 1025 1030 1035 1040
 Gly Met Val His His Arg His Arg Ser Ser Ser Thr Arg Ser Gly Gly
 1045 1050 1055
 Gly Asp Leu Thr Leu Gly Leu Glu Pro Ser Glu Glu Glu Ala Pro Arg
 1060 1065 1070
 Ser Pro Xaa Ala Pro Ser Glu Gly Thr Gly Ser Asp Val Phe Asp Gly
 1075 1080 1085
 Asp Leu Gly Met Gly Ala Ala Lys Gly Leu Gln Ser Leu Pro Ala His
 1090 1095 1100
 Asp Pro Ser Pro Leu Gln Arg Tyr Ser Glu Asp Pro Thr Val Pro Leu
 1105 1110 1115 1120
 Pro Ser Glu Thr Asp Gly Tyr Val Ala Pro Leu Thr Cys Ser Pro Gln
 1125 1130 1135
 Pro Glu Tyr Val Asn Gln Pro Asp Val Arg Pro Gln Pro Pro Ser Pro
 1140 1145 1150
 Gln Glu Gly Pro Leu Ser Pro Ala Arg Pro Thr Gly Ala Thr Leu Glu
 1155 1160 1165
 Arg Pro Lys Thr Leu Ser Pro Gly Lys Asn Gly Val Val Lys Asp Val
 1170 1175 1180
 Phe Ala Phe Gly Gly Ala Val Glu Asn Pro Glu Tyr Leu Ala Pro Arg
 1185 1190 1195 1200
 Gly Gly Ala Ala Pro Gln Pro His Leu Pro Pro Ala Phe Ser Pro Ala
 1205 1210 1215
 Phe Asp Asn Leu Tyr Tyr Trp Asp Gln Asp Pro Ser Glu Arg Gly Ala
 1220 1225 1230
 Pro Pro Ser Thr Phe Lys Gly Thr Pro Thr Ala Glu Asn Pro Glu Tyr
 1235 1240 1245
 Leu Gly Leu Asp Val Pro Val
 1250 1255

<210> 42
 <211> 3768
 <212> DNA
 <213> Rhesus Monkey

<400> 42
 atggagctgg cggcctggta ccgctggggg ctctctctcg ccctcttgcc ccccgagct 60
 gggggcacc aagtgtgcac cggcacagac atgaagctgc ggctccctgc cagtcccag 120
 acccacctgg acatgtctcg ccacctctac cagggtctgc aggtggtgca gggtaacctg 180
 gaactcacct acctgccac caatgccagc ctctccttcc tgcaggatat ccaggagggtg 240
 cagggtctacg tgctcatcgc tcacaaccaa gtgaggcagg tccactgca gaggctgcgg 300
 attgtgcgag gcacccagct ctttgaggac aactatgccc tggccgtgct agacaatgga 360
 gacctgtga acaataccac ccctgtcaca ggggcctccc caggaggcct gcgggagctg 420
 cagcttcgaa gcctcacaga gatcttgaaa ggaggggtct tgatccagcg gaacccccag 480
 ctctgtctacc aggacacgat tttgtggaag gacatcttcc ataagaacaa ccagctgggt 540
 ctcacactga tcgacaccaa ccgctctcgg gcctgccacc cctgttctcc agtgtgtaag 600
 ggctcccgtc gctggggaga gagttctgag gattgtcaga gcctgacgcg cactgtctgt 660
 gccggtggct gtgcccgtcg caaggggcca ctgcccactg actgctgcca tgagcagtgt 720
 gctgccggtc gcacgggccc caagcactct gactgcctgg cctgcctcca cttcaaccac 780
 agcggcatct gtgaactgca ctgcccagcc ctggctacct acaacacaga cacctttgag 840
 tccatgccca accccgaggg ccggtataca ttccggcgcca gctgtgtgac tgccctgtccc 900
 tacaactacc tttctacgga cgtgggatcc tgcacctcg tctgccccct gcacaaccaa 960
 gaggtgacag cggaggacgg aacacagcga tgtgagaagt gcagcaagcc ctgtgcccga 1020
 gtgtgctatg gtctgggcat ggagcacttg cgagaggtga gggcggtcac cagtgccaat 1080
 atccaggagt ttgctggctg caagaagatc tttgggagct tggcatttct gccagagagc 1140
 tttgatggcg acccagcctc caacaccgcc ccgcttcagc cggagcagct ccgagtgttt 1200
 gagactctgg aagagatcac aggttaccta tacatctcag catggccaga cagcctgcct 1260
 gaccttagcg tctctcagaa cctgcaagta atccggggac gaattctgca caatggcgcc 1320
 tactcactga ccttcgaagg gctgggcatc agctggctgg ggctgcgctc gctgagggaa 1380
 ctgggcagtg gactggccct catccaccat aacaccgcc tctgctttgt gcacagggtg 1440
 ccctgggacc agctcttccg gaaccgcac caagcctgc tccacactgc caaccggcca 1500
 gaggacgagt gtgtgggcga gggcctggcc tgccaccagc tgtgcgcccg agggcactgc 1560

tggggtccag	ggccccacca	gtgtgtcaac	tgcagccagt	tccttcgggg	ccaggagtgc	1620
gtggaggaat	gccgagtact	gcaggggctc	cccagggagt	atgtgaatgc	cagacactgt	1680
ttgccgtgcc	accctgagtg	tcagccccag	aatggctcag	tgacatgttt	tggaccggag	1740
gctgaccagt	gtgtggcctg	tgcccactat	aaggacctc	ccttctgcgt	ggccccgctgc	1800
cccagcgggtg	tgaaacctga	cctctcctac	atgcccatct	ggaagtttcc	agatgaggag	1860
ggcacgtgcc	agtcttgccc	catcaactgc	acctactcct	gtgtggacct	ggatgacaag	1920
ggctgccccg	ccgagcagag	agccagccct	ctgacgtcca	tcattctctgc	tgtggtgggc	1980
attctgctgg	tcgtggtctt	gggggtgggtc	tttggaatcc	tcattcaagcg	acggcagcag	2040
aagatccgga	agtacacgat	gcggaggctg	ctgcaggaaa	cggagctggt	ggagccactg	2100
acaccgagtg	gagcgatgcc	caaccaggcg	cagatgcgga	tcctgaaaga	gacggagctg	2160
aggaaaggta	agggtgcttg	atctggagct	tttggcacag	tctacaaggg	catctggatc	2220
cctgatgggg	agaatgtgaa	aattccagtg	gccatcaaa	tggtgaggga	aaacacatcc	2280
cccaaagcca	acaaagaaat	cttagacgaa	gcattatgtga	tggctggtgt	gggctccccca	2340
tatgtctccc	gcctcctggg	catctgcctg	acatccacgg	tgcagctggt	gacacagctt	2400
atgccctatg	gctgcctctt	agaccatgtc	cgagaaaacc	gcggacgcct	gggctcccag	2460
gacctgctga	actggtgtat	gcagattgcc	aaggggatga	gctacctgga	ggatgtgcgg	2520
ctcgtaacaca	gggacttggc	tgctcggaac	gtgctggtca	agagtcccaa	ccatgtcaaa	2580
attacagact	ttgggctggc	tcggctgctg	gacattgacg	agacagagta	ccatgcagat	2640
gggggcaagg	tgcccatcaa	gtggatggcg	ctggagtcca	ttctccgacg	gcgggtccacc	2700
caccagagtg	atgtgtggag	ttatggtgtg	actgtgtggg	agctgatgac	ttttggggcc	2760
aaaccttacg	atgggatccc	agcccgggag	atccctgacc	tgctggaaaa	gggggagcgg	2820
ctgccccagc	cccccatctg	caccattgat	gtctacatga	tcattggtcaa	atgttggatg	2880
attgactctg	aatgtcggcg	gagattccgg	gagttggtgt	cggaaattctc	ccgcattggc	2940
agggaccccc	agcgctttgt	ggtcatccag	aatgaggact	tgggcccagc	cagtcccttg	3000
gacagcacct	tctaccgctc	actgctggag	gacgatgaca	tgggggacct	ggtggatgtc	3060
gaggagtatc	tggtacccca	gcagggcttc	ttctgtccag	accctgcccc	gggcaactggg	3120
ggcatggtcc	accacaggca	ccgcagctca	tctaccagga	gtggcggtgg	ggacctgacg	3180
ctagggctgg	agccctctga	agaggaggcc	cccaggcttc	cacgggcacc	ctccgaaggg	3240
actggctctg	atgtatttga	tggtgacctc	ggaatggggg	cagccaaggg	gctgcaaagc	3300
ctccccgcac	atgaccccag	ccctctacag	cggtaacagt	aggaccccac	ggtacccttg	3360
ccttctgaga	ctgacggcta	cgttgcccc	ctgacctgca	gtccccagcc	cgaatatgtg	3420
aaccagccag	atgttcggcc	acagccccct	tcgccccaa	agggccctct	gtctcctgcc	3480
cgacctactg	gtgccactct	ggaaaggccc	aagactctct	cccaggggaa	gaatggggtt	3540
gtcaaagacg	tttttgccct	tgggggtgct	gtggagaacc	ccgagtactt	ggcaccctcg	3600
ggaggagctg	ccctcagccc	ccaccttctc	cctgccttca	gccagcctt	cgacaacctc	3660
tattactggg	accaggaccc	atcagagcgg	ggggtctccac	ctagcacctt	caaagggaca	3720
cctacggcag	agaaccacga	gtacctgggt	ctggacgtgc	cagtgtga		3768

<210> 43

<211> 3768

<212> DNA

<213> Rhesus Monkey

<400> 43

atggagctgg	cgccctggta	ccgctggggg	ctcctcctcg	ccctcttgcc	ccccggagct	60
gccccacccc	aagtgtgcac	cggcacagac	atgaagctgc	ggctccctgc	cagtcccag	120
accacactgg	acatgctccg	ccacctctac	cagggctgcc	aggtggtgca	gggtaacctg	180
gaactcacct	acctgcccac	caatgccagc	ctctccttcc	tgcaggatat	ccaggaggtg	240
cagggctacg	tgctcatcgc	tcacaaccaa	gtgaggcagg	tcccactgca	gaggctgcgg	300
attgtgcgag	gcacccagct	ctttgaggac	aactatgccc	tggccgtgct	agacaatgga	360
gacctgctga	acaataccac	ccctgtcaca	ggggcctccc	caggaggcct	gcgggagctg	420
cagcttcgaa	gcctcacaga	gatcttgaaa	ggaggggtct	tgatccagcg	gaacccccag	480
ctctgctacc	aggacacgat	tttgtggaag	gacatcttcc	ataagaacaa	ccagctggct	540
ctcacactga	tcgacaccaa	ccgctctcgg	gacctgccac	cctgttctcc	agtgtgtaag	600
ggctcccgct	gctggggaga	gagttctgag	gattgtcaga	gactgacgcg	cactgtctgt	660
gccggtggct	gtgcccgtg	caaggggcca	ctgcccactg	actgctgcca	tgagcagtgt	720
gctgccggct	gcacggggcc	caagcactct	gactgcctgg	cctgcctcca	cttcaaccac	780
agcggcatct	gtgagctgca	ctgcccagcc	ctggctacct	acaacacaga	cacctttgag	840
tccatgccca	accccagggg	ccggtatata	ttcgccgcca	gctgtgtgac	tgccctgtccc	900
tacaactacc	tttctacgga	cgtgggatcc	tgcacctcgt	tctgccccct	gcacaaccaa	960
gaggtgacag	cggaggacgg	aacacagcga	tgtgagaagt	gcagcaagcc	ctgtgcccga	1020
gtgtgctatg	gtctgggcat	ggagcacttg	cgagaggtga	gggcggtcac	cagtgccaat	1080
atccaggagt	ttgctggctg	caagaagatc	tttgggagct	tggcatttct	gccagagagc	1140
tttgatggcg	accagcctc	caacaccgcc	ccgcttcagc	cggagcagct	ccgagtgttt	1200

gagactctgg	aagagatcac	aggttaccta	tacatctcag	catggccaga	cagcctgcct	1260
gaccttagcg	tcctccagaa	cctgcaagta	atccggggac	gaattctgca	caatggcgcc	1320
tactcactga	ccctgcaagg	gctgggcata	agctggctgg	ggctgcgctc	gctgagggaa	1380
ctgggcagtg	gactggccct	catccaccat	aacacccgcc	tctgctttgt	gcacacgggtg	1440
ccctgggacc	agctcttccg	gaacccgcac	caagccctgc	tcacactgc	caaccggcca	1500
gaggacgagt	gtgtgggcga	gggcctggcc	tgccaccagc	tgtgcgccc	agggcactgc	1560
tggggctccag	ggccaccca	gtgtgtcaac	tgcagccagt	tccttcgggg	ccaggagtgc	1620
gtggaggaat	gccgagtact	gcaggggctc	cccagggagt	atgtgaatgc	cagacactgt	1680
ttgccgtgcc	accctgagt	tcagccccag	aatggctcag	tgacatgttt	tggaccggag	1740
gctgaccagt	gtgtggcctg	tgcccactat	aaggaccctc	ccttctgcgt	ggcccgtgc	1800
cccagcgggtg	tgaaacctga	cctctcctac	atgcccatct	ggaagtctcc	agatgaggag	1860
ggcacgtgcc	agtcttgccc	catcaactgc	accacccct	gtgtggacct	ggatgacaag	1920
ggctgccccg	ccgagcagag	agccagccct	ctgacgtcca	tcctctctgc	tgtgggtgggc	1980
attctgctgg	tcgtggtctt	gggggtggtc	tttgggaatcc	tcctcaagcg	acggcagcag	2040
aagatccgga	agtagacgat	gcggaggctg	ctgcaggaaa	cggagctggt	ggagccactg	2100
acaccgagtg	gagcgatgcc	caaccaggcg	cagatgcgga	tcctgaaaga	gacggagctg	2160
aggaagggtga	aggtgcttgg	atctggagct	tttggcacag	tctacaaggg	catctggatc	2220
cctgatgggg	agaatgtgaa	aattccagt	gccatcaaag	tgttgaggga	aaacacatcc	2280
cccaaagcca	acaaagaaat	cttagacgaa	gcataatgtga	tggctggtgt	gggctcccca	2340
tatgtctccc	gcctcctggg	catctgcctg	acatccacgg	tgacgtggt	gacacagctt	2400
atgccctatg	gctgcctctt	agaccatgtc	cgagaaaacc	gcggacgcct	gggctcccag	2460
gacctgctga	actggtgtat	gcagattgcc	aaggggatga	gctacctgga	ggatgtgcgg	2520
ctcgtagaca	gggacttggc	tgctcggaac	gtgctggtca	agagtcccaa	ccatgtcaaa	2580
attacagact	ttgggctggc	tcggctgctg	gacattgacg	agacagagta	ccatgcagat	2640
gggggcaagg	tgcccatcaa	gtggatggcg	ctggagtcca	ttctccgacg	gcgggtcacc	2700
caccagagtg	atgtgtggag	ttatggtgtg	actgtgtggg	agctgatgac	ttttggggcc	2760
aaaccttacg	atgggatccc	agcccgggag	atccctgacc	tgctggaaaa	gggggagcgg	2820
ctgccccagc	cccccatctg	caccattgat	gtctacatga	tcattggtcaa	atgttggatg	2880
attgactctg	aatgtcggcc	gagattccgg	gagttggtgt	cgggaattctc	ccgcatggcc	2940
agggaccccc	agcgctttgt	ggtcatccag	aatgaggact	tgggcccagc	cagtccttg	3000
gacagcacct	tctaccgctc	actgctggag	gacgatgaca	tgggggacct	ggtggatgct	3060
gaggagtatc	tggtaccca	gcagggcttc	ttctgtccag	accctgcccc	gggcactggg	3120
ggcatgggtcc	accacaggca	ccgcagctca	tctaccagga	gtggcggtgg	ggacctgacg	3180
ctagggctgg	agccctctga	agaggaggcc	cccaggtctc	cacgggcacc	ctccgaaggg	3240
actggctctg	atgtatttga	tggtgacctg	ggaatggggg	cagccaaggg	gctgcaaagc	3300
ctccccgcac	atgaccccag	cctctacag	cggtacagt	aggaccccac	ggtacccctg	3360
ccttctgaga	ctgacggcta	cgttgcccc	ctgacctgca	gtccccagcc	cgaatatgtg	3420
aaccagccag	atgttcggcc	acagccccct	tcgccccaa	agggccctct	gtctcctgcc	3480
cgacctactg	gtgccactct	ggaaaggccc	aagactctct	cccagggaa	gaatggggtt	3540
gtcaaagacg	tttttgccct	tgggggtgct	gtggagaacc	ccgagtactt	ggcaccgccg	3600
ggaggagctg	ccccccagcc	ccaccttct	cctgccttca	gcccagcctt	cgacaacctc	3660
tattactggg	accaggaccc	atcagagcgg	ggggctccac	ctagcacctt	caaagggaca	3720
cctacggcag	agaaccacga	gtacctgggt	ctggacgtgc	cagtgtga		3768

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N15/861 C12N5/16 C07K14/71 C12P21/02
A61K38/17 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, SEQUENCE SEARCH, BIOSIS, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 02/14503 A (HAND ZIMMERMANN SUSAN ;CORIXA CORP (US); FOY TERESA M (US); KALOS) 21 February 2002 (2002-02-21) page 3, line 1 -page 6, line 9 page 9, line 14 -page 14, line 10 page 38, line 12 -page 41, line 4 page 56, line 22 -page 83, line 29; example 1 Sequence Listing: SEQ ID NOs: 1 and 2	1-20
Y	WO 02/13847 A (HAND ZIMMERMANN SUSAN ;CORIXA CORP (US); CHEEVER MARTIN A (US); GA) 21 February 2002 (2002-02-21) page 2, line 9 -page 4, line 13 page 6, line 4 -page 17, line 11 page 23, line 15 -page 34, line 3 Sequence Listing: SEQ ID NOs: 1 and 2 --- -/--	1-20

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *Z* document member of the same patent family

Date of the actual completion of the international search

27 May 2004

Date of mailing of the international search report

04/06/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Donath, C

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5 869 445 A (DISIS MARY L ET AL) 9 February 1999 (1999-02-09) column 2, line 25 -column 3, line 12 column 6, line 27 - line 53; example 4 Sequence Listing: SEQ ID NOs: 1 and 2	1-20
A	FENDLY B M ET AL: "SUCCESSFUL IMMUNIZATION OF RHESUS MONKEYS WITH THE EXTRACELLULAR DOMAIN OF P185HER2: A POTENTIAL APPROACH TO HUMAN BREAST CANCER" VACCINE RESEARCH, MARY ANN LIEBERT, INC., PUBLISHERS, US, vol. 2, no. 3, 1993, pages 129-139, XP009030428 abstract	1-20
A	DISIS M L ET AL: "HER-2/NEU PROTEIN: A TARGET FOR ANTIGEN-SPECIFIC IMMUNOTHERAPY OF HUMAN CANCER" ADVANCES IN CANCER RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 71, 1991, pages 343-371, XP000982776 ISSN: 0065-230X the whole document	1-20
A	HUNG M-C ET AL: "HER-2/NEU-TARGETING GENE THERAPY - A REVIEW" GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 159, no. 2, 1995, pages 65-71, XP002057855 ISSN: 0378-1119 the whole document	1-20

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 8-11 and 14-20 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0214503	A	21-02-2002	AU 9500801 A	25-02-2002
			CA 2419533 A1	21-02-2002
			EP 1366153 A2	03-12-2003
			NO 20030714 A	11-04-2003
			WO 0214503 A2	21-02-2002
			US 2002193329 A1	19-12-2002
WO 0213847	A	21-02-2002	AU 8336001 A	25-02-2002
			WO 0213847 A2	21-02-2002
			US 2003157119 A1	21-08-2003
US 5869445	A	09-02-1999	US 5801005 A	01-09-1998
			US 2002019331 A1	14-02-2002
			AU 708237 B2	29-07-1999
			AU 5522296 A	16-10-1996
			BR 9607889 A	10-08-1999
			CA 2216601 A1	03-10-1996
			CN 1183117 A	27-05-1998
			CZ 9703096 A3	14-01-1998
			EP 1418235 A2	12-05-2004
			EP 0817846 A1	14-01-1998
			HU 9801826 A2	30-11-1998
			JP 11502710 T	09-03-1999
			NO 974502 A	27-11-1997
			NZ 306616 A	30-03-2001
			WO 9630514 A1	03-10-1996
			US 2002055614 A1	09-05-2002
			US 6075122 A	13-06-2000
			US 5726023 A	10-03-1998
			US 5876712 A	02-03-1999
			US 5846538 A	08-12-1998
			US 2004082758 A1	29-04-2004